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1. INTRODUCTION
As defined by the European Commission, nanomaterial is a natural, incidental or 
manufactured material containing particles in an unbound state or as an aggregate or 
agglomerate in which ≥ 50% of the particles in the number size distribution have one or 
more external dimensions in the size range 1 to 100 nm. In specific cases and where 
warranted by concerns for the environment, health, safety or competition, the number size 
distribution threshold of 50% may be replaced with a threshold between 1 and 50%.1 
Engineered nanomaterials (ENMs) refer to man-made nanomaterials. Materials in the 
nanometer range often possess unique physical, optical, electronic, and biological properties 
compared with larger particles, such as the strength of graphene,2 the electronic properties of 
carbon nanotubes (CNTs),3 the antibacterial activity of silver nanoparticles4 and the optical 
properties of quantum dots (QDs).5 The unique and advanced properties of ENMs have led 
to a rapid increase in their application. These applications include aerospace and airplanes, 
energy, architecture, chemicals and coatings, catalysts, environmental protection, computer 
memory, biomedicine and consumer products. Driven by these demands, the worldwide 
ENM production volume in 2016 is conservatively estimated in a market report by Future 
Markets to be 44,267 tons or ≥ $5 billion.6
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As the production and applications of ENMs rapidly expand, their environmental impacts 
and effects on human health are becoming increasingly significant.7 Due to their small sizes, 
ENMs are easily made airborne.8 However, no accurate method to quantitatively measure 
their concentration in air currently exists. A recently reported incident of severe pulmonary 
fibrosis caused by inhaled polymer nanoparticles in seven female workers obtained much 
attention.9 In addition to the release of ENM waste from industrial sites, a major release of 
ENMs to environmental water occurs due to home and personal use of appliances, cosmetics 
and personal products, such as shampoo and sunscreen.10 Airborne and aqueous ENMs pose 
immediate danger to the human respiratory and gastrointestinal systems. ENMs may enter 
other human organs after they are absorbed into the bloodstream through the gastrointestinal 
or respiratory systems.11,12 Furthermore, ENMs in cosmetics and personal care products, 
such as lotion, sunscreen and shampoo may enter human circulation through skin 
penetration.13 ENMs are very persistent in the environment and are slowly degraded. The 
dissolved metal ions from ENMs can also revert back to nanoparticles under natural 
conditions.14 ENMs are stored in plants, microbes and animal organs and can be transferred 
and accumulated through the food chain.15,16 In addition to the accidental entry of ENMs 
into human and biological systems, ENMs are also purposefully injected into or enter 
humans for medicinal and diagnostic purposes.17 Therefore, interactions of ENMs with 
biological systems are inevitable.
In addition to engineered nanomaterials, there are also naturally existing nanomaterials such 
as proteins and DNA molecules, which are key components of biological systems. These 
materials, combined with lipids and organic and inorganic small molecules, form the basic 
units of living systems –cells.18 To elucidate how nanomaterials affect organs and 
physiological functions, a thorough understanding of how nanomaterials perturb cells and 
biological molecules is required (Figure 1). Rapidly accumulating evidence indicates that 
ENMs interact with the basic components of biological systems, such as proteins, DNA 
molecules and cells.19-21 The driving forces for such interactions are quite complex and 
include the size, shape and surface properties (e.g., hydrophobicity, hydrogen-bonding 
capability, pi-bonds and stereochemical interactions) of ENMs.22-25
Evidence also indicates that chemical modifications on a nanoparticle’s surface alter its 
interactions with biological systems.26-28 These observations not only support the 
hypothesis that basic nano-bio interactions are mainly physicochemical in nature but also 
provide a powerful approach to controlling the nature and strength of a nanoparticle’s 
interactions with biological systems. Practically, a thorough understanding of the 
fundamental chemical interactions between nanoparticles and biological systems has two 
direct impacts. First, this knowledge will encourage and assist experimental approaches to 
chemically modify nanoparticle surfaces for various industrial or medicinal applications. 
Second, a range of chemical information can be combined with computational methods to 
investigate nano-biological properties and predict desired nanoparticle properties to direct 
experiments.29-31
The literature regarding nanoparticle-biological system interactions has increased 
exponentially in the past decade (Figure 2). However, a mechanistic understanding of the 
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chemical basis for such complex interactions is still lacking. This review intends to explore 
such an understanding in the context of recent publications.
A breakthrough technology cannot prosper without wide acceptance from the public and 
society; that is, it must pose minimal harm to human health and the environment. 
Nanotechnology is now facing such a critical challenge. We must elucidate the effects of 
ENMs on biological systems (such as biological molecules, human cells, organs and 
physiological systems). Accumulating experimental evidence suggests that nanoparticles 
interact with biological systems at nearly every level, often causing unwanted physiological 
consequences. Elucidating these interactions is the goal of this review. This endeavor will 
help regulate the proper application of ENMs in various products and their release into the 
environment. A more significant mission of this review is to direct the development of 
“safe-by-design” ENMs, as their demands for and applications continue to increase.
2. FACTORS AFFECTING NANOPARTICLE-BIOLOGICAL SYSTEM 
INTERACTIONS
2.1. Nanoparticles
The extremely large surface area of nanoparticles results in the strong adsorption of various 
molecules to reduce nanoparticle surface energy. Completely “naked” nanoparticles are 
nearly non-existent. The interactions between nanoparticles and biological systems (nano-
bio interactions) are actually driven by modified nanoparticles in biological media, such as 
nanoparticle complexes or their aggregates.32 The real identity of nanoparticles in biological 
systems is determined by their intrinsic properties, such as their size, shape, surface charge 
and hydrophobicity (Scheme 1). Therefore, a rigorous characterization of nanoparticles is 
essential prior to investigating nano-bio interactions.
A very large collection of methods has been used to characterize nanoparticle physical and 
chemical properties. Transmission electron microscopy (TEM), scanning electron 
microscopy (SEM) and atomic force microscopy (AFM) provide information on 
nanoparticle morphology.33 Dynamic light scattering (DLS) provides information on the 
hydrodynamic radii of nanoparticles in solution.34 The surface charge properties of 
nanoparticles can be determined with ζ-potential measurements.35 Auger electron 
spectroscopy, X-ray photoelectron spectroscopy (XPS), time-of-flight mass spectrometry 
(TOF MS) and elemental analyses reveal chemical composition details of nanoparticles.36,37 
Surface ligands or adsorbed molecules can be identified with magic angle spinning nuclear 
magnetic resonance (MAS NMR), liquid chromatography mass spectroscopy (LC-MS) and 
Fourier-transform infrared spectroscopy (FTIR).38-40 Surface-enhanced Raman 
spectroscopy (SERS) is also among the most frequently applied analytical methods for 
characterizing nanoparticles.41
2.2. Biological Factors
In biological systems, nanoparticles are surrounded by excessive amounts of biological 
molecules, which may result in the saturation of the nanoparticle surface. This phenomenon 
occurs whether the nanoparticles are present in the body or in a cellular environment. Such 
Mu et al. Page 3













biologically modified nanoparticles are the real participants in nano-bio interactions.32 
These modifications also affect cell binding events and the internalization of nanoparticles. 
Inside the cell, nanoparticles tend to localize in certain cellular organelles and affect specific 
cell regions.42-44
In biological fluids, nanoparticles interact with phospholipids, proteins, DNA and small 
metabolites. Phospholipids are the main components in the pulmonary system and cell 
membranes, consisting of a negatively charged phosphate group (head) and a hydrophobic 
carbon chain (tail).18 Nanoparticles may interact with the charged head and/or the 
hydrophobic tail depending on their surface hydrophobicity. Nanoparticles spontaneously 
adsorb proteins in the bloodstream or biological fluid. Proteins are folded peptides with 
different sizes, shapes and net charges at physiological pH. Protein surfaces also exhibit 
varying hydrophobicity depending on the nature of the exposed amino acid residues.18 All 
of these properties may affect the stoichiometry and orientation of their bindings to 
nanoparticles. Nanoparticles may also bind DNA molecules in biological systems. DNA 
molecules carry negative charges from the phosphate groups and base π-systems.18 Single- 
or double-strand DNA molecules can bind to nanoparticles through electrostatic, π-π 
stacking and hydrophobic interactions (Section 3.3). Therefore, molecular interactions of 
nanoparticles in biological environments involve interactions with proteins, DNA, 
phospholipids, small molecules and inorganic ions. Such interactions are further 
complicated by the kinetics and thermodynamics of the nanoparticle associations with each 
component.
The organ from which a cell originates influences nanoparticle-cell interactions. First, 
different cell types have different shapes. Human erythrocytes exhibit a smooth, spherical 
shape, while ependymal cells demonstrate a long, slender shape.45,46 These differences 
produce in different cellular responses when internalizing foreign matter, such as 
nanoparticles. Second, plasma membranes from different cell types have different lipid 
compositions, which influence the physical properties of membranes and make them 
function differently. Third, different types of cells express different membrane receptors. 
For example, macrophages express a large number of scavenger receptors that help 
internalize foreign matter non-specifically.47 Fourth, different cellular organelles have 
various impacts on nanoparticles. Lysosomes are acidic organelles, while the cytoplasm is 
nearly neutral. Nanoparticles in lysosomes may undergo degradation, which may result in 
the release of ions and a toxic state.48 However, drug cargos may be preferably released in 
acidic environments for therapeutic purposes.49
3. NANOPARTICLE-BIOMOLECULE INTERACTIONS
Nanoparticles enter the human body via multiple routes, encountering various biomolecules 
regardless of the pathway by which they enter the human body. Airborne nanoparticles may 
enter the human body through inhalation. In the lungs, nanoparticles exhibit strong 
interactions with the lung surfactant system, which consists of proteins and 
phospholipids.50,51 Engineered medical nanoparticles are generally administered into the 
circulation system through intravenous injection. Injected nanoparticles first interact with 
blood proteins before being distributed in various organs.52 Some nanoparticles may also 
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enter the cell nucleus and interact with nucleic acids, such as DNA.53 Furthermore, 
nanoparticles in the blood or cells also adsorb small molecules, such as amino acids, biotin 
and folic acid. The depletion of small metabolites may also contribute to the toxicity of 
nanoparticles.54 In this section, we discuss interactions of nanoparticles with proteins, lipids, 
DNA and small molecules. We focus on the characterization and mechanistic elucidation of 
these interactions.
3.1. Nanoparticle-Phospholipid Interactions
3.1.1. Interaction of Nanoparticles with Phospholipids in Pulmonary 
Surfactant Solutions—Phospholipids and proteins constitute pulmonary surfactant 
system. Inhaled nanoparticles inevitably interact with these components. The interactions 
between nanoparticles and pulmonary surfactant system determine nanoparticles’ pulmonary 
toxicity or drug delivery efficacy. Therefore, understanding these interactions and 
effectively regulate these interactions are imperative for safe nanotechnology and better 
nanomedicine. Pulmonary surfactant solutions have been used to mimic human pulmonary 
surfactant system for mechanistic studies. The nature of nanoparticle-phospholipid 
interactions can be investigated after isolating and identifying nanoparticle-bound surfactant 
molecules and characterizing the properties of nanoparticle-surfactant complexes. 
Nanoparticle-bound lipid molecules can be isolated by size exclusion chromatography55 or 
thin layer chromatography50 and structurally identified by NMR55 or MS.51 Nanoparticle-
phospholipid interactions can also be measured by identifying alterations in nanoparticle 
physicochemical properties. Surfactant molecule coatings alter nanoparticle sizes and 
dispersion states, which can be measured using DLS,56 TEM56,57 or SEM.58 Surfactant 
molecules can also alter the surface charge status of nanoparticles, as determined with ζ-
potential analysis.56 Binding of surfactant molecules onto the surfaces of nanoparticles may 
alter their surface plasma resonance (SPR) absorption and can also be determined using UV-
Vis absorption spectroscopy.56 The surface properties of pulmonary surfactant solutions, 
such as equilibrium and dynamic surface tension behavior under the pulsation of samples, 
are also used to evaluate the effects of nanoparticles.57,59
Dipalmitoyl phosphatidylcholine (DPPC, the most abundant surfactant molecule in a 
pulmonary surfactant mixture; also termed Survanta) is strongly adsorbed onto the surface 
of nanoparticles (e.g., carbon-based nanoparticles), forming a rigid monolayer. The binding 
of long aliphatic hydrocarbon chains to carbon nanoparticle surfaces results in increased 
nanoparticle surface charge, size and stability. Adsorption onto a hydrophobic surface is also 
energetically favorable for DPPC.56 Although proteins bind to multi-walled CNTs 
(MWNTs) with different binding patterns depending on the surface functionalization of the 
CNTs, the surfactant lipid may nonspecifically adsorb onto different MWNTs.50 The 
adsorption of lipids onto the surface of carbon-based nanoparticles may affect their in vitro 
and in vivo behavior. When coated with DPPC, nanoscale carbon black and crocidolite 
asbestos increase reactive oxygen species (ROS) generation in primary bronchial epithelial 
cells and in A549 alveolar epithelial carcinoma cells, while fetal bovine serum protein-
coated nanoparticles protect cells from oxidative insult.60 However, in another study, DPPC-
coated, single-walled CNTs (SWNTs) did not generate cytotoxic or fibrogenic effects in 
vitro. Lung fibrosis in mice can be induced by SWNTs with or without DPPC coating, 
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indicating that DPPC does not significantly mask the bioactivity of SWNTs in vivo.58 
Surfactants and the nanoparticle system can also affect each other. Phospholipids have been 
shown to stabilize colloidal GNPs by forming lipid bilayers on the particle surface, while the 
presence of GNPs reduces the surface activity of surfactants, such as their ability to form a 
surface film or the ability of this film to reach low surface tension during compression.57 
Size of particles also affects their interactions with lipids. TiO2 nanoparticles but not 
microsized particles increase the adsorption surface tension of the surfactant in a dose-
dependent manner. These phenomena are also observed during surface area cycling in the 
presence of nanoparticles. TEM observations have demonstrated that lamellar body-like 
structures are deformed and decreased in size, with the formation of unilamellar vesicles.61
The binding events of proteins to nanoparticles most likely affect the surfactant interactions 
of nanoparticles. Interactions of polymeric nanoparticles with lipids in human plasma have 
been investigated using size exclusion chromatography, NMR and enzymatic assays. 
Nanoparticles bind cholesterol, triglycerides and phospholipids in human plasma. The 
binding events depend on the nanoparticle surface properties. A higher cholesterol content is 
present in the pellets of hydrophobic nanoparticles when compared to those of more 
hydrophilic nanoparticles.55
3.1.2. Interactions Between Nanoparticles and Model Membranes—Model 
membranes are organized lipids that mimic the arrangement of lipids in natural cell 
membranes. Interactions between nanoparticles and model membranes have been 
investigated using biophysical approaches to evaluate the cellular translocation of 
nanoparticles and the potential effects of nanoparticles on the integrity of the cell membrane. 
Lipid monolayers, bilayers and liposomes are three widely used model membranes.62
The surface pressure-area (π-A) isotherm is an indicator of the monolayer properties of an 
amphiphilic material and is obtained by measuring the surface pressure as a function of the 
water surface area available to each molecule.63 The isotherm is recorded by compressing 
the film at a constant rate while continuously monitoring the surface pressure. Although π-A 
isotherm measurements have been used to study the properties of model lipid monolayers in 
the presence of nanoparticles, this approach is limited to monolayer membranes that lack 
anchoring membrane proteins.64 AFM can be used to measure the effects of nanoparticles 
on morphological changes of Langmuir-Blodgett (LB) films. AFM measures subtle 
morphological details of soft matter at subnanometer levels, enabling the observation of the 
formation of lipid bilayers and their disruption by nanoparticles.65-68 A liquid crystal-based 
system has been developed to study the molecular interactions between protein-coated 
nanoparticles and a liquid crystal-supported model membrane. The spatial and temporal 
organization of the lipid monolayer is coupled to the orientation of the liquid crystal, 
permitting the direct observation of the dynamic characteristics of the lipid monolayer.69,70 
Differential scanning calorimetry (DSC)68,71,72 and isothermal titration calorimetry (ITC)73 
can also be used to measure nanoparticle-induced thermodynamic changes in supported 
membranes or liposomes. A quartz crystal microbalance (QCM) with dissipation monitoring 
can be used for real-time monitoring of nanoparticle-lipid membrane interactions.74 
Fluorescence microscopy,65,75 fluorescence spectroscopy,68 fluorescence correlation 
spectroscopy (FCS),73 Föster resonance energy transfer,73,76 NMR77 and liposomal leakage 
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assay78 have all been used to study the biophysical changes and disruptions of model lipid 
membranes or liposomes by nanoparticles.
Hydrophobic69,70 and electrostatic interactions74,78 may serve major roles in nanoparticle-
lipid membrane interactions. The interactions of nanoparticles with the lipid membranes 
lead to changes in both components, such as disruption of the lipid membrane and the 
modification of the nanoparticle surface properties. Guanidinylated dendrimers that carry a 
positive surface charge first adhere to the liposomal membrane through binding to 
negatively charged phosphate groups. The dendrimer surfaces then become hydrophobic due 
to charge neutralization. The dendrimers are consequently transported through the 
hydrophobic liposomal membrane.68 Other polycationic polymers (i.e., polyamidoamine 
dendrimers, pentanol-core polyamidoamine dendrons, polyethyleneimine and 
diethylaminoethyl dextran) also induce the disruption of supported bilayers, including the 
formation of holes, membrane thinning and membrane erosion.79 Polycationic polymers 
disrupt the liquid phase but not the gel phase of dimyristoylphosphatidylcholine bilayers.77 
Electrostatic interactions can also occur between protein-coated CNTs and liposomes, 
leading to liposome leakage.78 Surface charged polystyrene nanoparticles bind to liposomes 
and induce surface reconstruction of the phospholipid membranes, indicating a potential 
structural perturbation of the cellular membrane by nanoparticles (Figure 3).73 Nanoparticle-
induced lipid bilayer rearrangements are limited to bubble-like liposomes, not supported 
bilayers.76 QDs can insert into lipid membranes and induce a current burst under an electric 
field, indicating their potential to perturb neuronal and muscle cells.80,81 Cationic 
phosphorus dendrimers can alter the thermotropic behavior of lipid bilayers by reducing the 
cooperativity of the phospholipids; this effect is membrane surface charge-dependent.71 A 
model has been proposed to describe the behavior of nanoparticles at the air-liquid interface 
of alveoli (Figure 4). Nanoparticles inhaled into the alveolar space during breathing may 
interact with continuous surfactant films. The nanoparticles then become wetted and lined 
with phospholipid bilayers.57
In addition to the lipid membranes properties, the factors that influence nanoparticle-lipid 
interactions include nanoparticle dose, composition, size and surface chemistry. 
Hydrophobic polyorganosiloxane nanoparticles do not substantially affect the structural 
organization of a model pulmonary surfactant film at low concentrations (e.g., 10 μg/mL) 
but significantly affect such properties at high concentrations (e.g., 3000 μg/mL).82 
Polystyrene nanoparticles with a diameter of 20 nm demonstrate greater interactions with 
the endothelial model membrane than those with a diameter of > 60 nm.64 Perturbations 
from nanoparticles may cause pore formation in lipid bilayers.65,66,79 Studies of 
polycationic polyamidoamine dendrimers and supported dimyristoylphosphatidylcholine 
bilayers have demonstrated that G7 dendrimers (8.0-8.2 nm) but not G3 dendrimers (3.5-4.1 
nm) induce the formation of holes in lipid bilayers. G5 dendrimers (4.3-6.6 nm) have a 
reduced effect when compared to G7 dendrimers but had no effect when their amine end 
groups were replaced with acetamide groups, indicating the role of surface chemistry.67 The 
density of the functional groups also affects the interactions. Lightly guanidinylated 
dendrimeric derivatives act as “molecular glue” by adhering to liposomes, while highly 
guanidinylated dendrimeric derivatives induce liposome fusion.68 The crucial role of 
nanoparticle surface hydrophobicity has also been demonstrated. Hydrophobic, cholesterol-
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coated GNPs interact with DPPC vesicles and decrease their melting point, while 
hydrophilic nanoparticles increase the melting point of DPPC vesicles.72 The properties of 
model membranes, such as membrane surface charge71 and cholesterol content, also affect 
these interactions. A high cholesterol content in the phospholipid/cholesterol monolayer 
makes the lipids more susceptible to disruption by protein-coated GNPs.69
The development of efficient nanocarrier systems based on model membrane studies 
requires a good correlation between model systems and cellular studies. The effects of the 
size and surface chemistry of polymeric nanoparticles in model membranes correlate well 
with cell membrane disruption and cellular uptake.83-86
The interactions of nanoparticles with model membranes have also been investigated by 
molecular simulation approaches. Although computational methods cannot fully mimic 
complex biological systems, they facilitate an enhanced mechanistic understanding of their 
interactions and improved property predictions. The interactions of carbon nanoparticles, 
polymers and nanocrystals with lipid bilayers have been simulated by all-atom and coarse-
grained approaches.87-94 The influences of nanoparticle size, surface chemistry, 
hydrophobicity, shape and bilayer properties on the interaction mechanisms have been 
studied, and the results have yielded explanations for some experimental 
outcomes.87,88,90,93,95-98 ENREF 70
In summary, the investigation of nanoparticle-lipid membrane interactions through 
molecular simulations, biophysical characterization and cellular studies may collectively 
unravel the mechanisms of these processes and elucidate regulation strategies. Such 
developments will benefit nanotechnology-based drug delivery and the rational reduction of 
nanotoxicity.
3.2. Nanoparticle-Protein Interactions
The interactions between nanoparticles and proteins are complex. Nanoparticles are 
generally surrounded by plasma proteins upon entering the circulatory system. As 
nanoparticles enter cells and are distributed into different organs, they are also in close 
contact with cellular proteins. Protein binding-induced changes in the surface properties of 
nanoparticles affect their biodistribution and clearance.99 Moreover, conformational changes 
in bound proteins may expose unexpected epitopes to activate cell signaling.100 The 
interactions of nanoparticles with proteins are dynamic processes and governed by 
properties of both components. The physicochemical changes in nanoparticles or proteins 
also allow the characterization of the thermodynamic and kinetic processes of their 
interactions.
3.2.1. Determination of Nanoparticle-Protein Interactions—Similar to drug-protein 
or protein-protein interactions, nanoparticle-protein interactions are also characterized by 
binding affinity, stoichiometry and kinetic properties. Determining these properties helps us 
understand the chemical and dynamic nature of these interactions. Modulating these 
properties by modified nanoparticles may prevent unwanted interactions or enhance specific 
binding events.
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3.2.1.1. Determination of Binding Affinity and Stoichiometry and Identification of 
Binding Sites: Steady-state and time-resolved fluorescence spectroscopy are used to study 
nanoparticle-protein binding affinities, complex formation and binding-induced protein 
conformational changes.19 The dependence of protein fluorescence intensity or lifetime on 
quencher (nanoparticle) concentration follows the Stern-Volmer equation (1):
(1)
where F0, F, τ0 and τ represent the initial or modified fluorescence intensity or lifetime, 
respectively. Ksv is the Stern-Volmer constant, and [Q] is the quencher (nanoparticle) 
concentration.101
Fluorescence polarization permits the detection of interacting macromolecules in 
homogenous solutions and can quantify nanoparticle-protein interactions based on the 
change in rotational freedom of the fluorescent molecule upon complex formation.23,101 An 
advantage of fluorescence polarization is that it avoids complex separation, which may 
induce the denaturation of proteins or interrupt reaction equilibria. The binding ratio can be 
determined on the basis of fluorescence polarization measurements.
Stepwise photobleaching has been used to characterize nanoparticle-protein interactions. 
Both the protein and nanoparticles are labeled with fluorescence dyes. The protein-
nanoparticle binding ratio is estimated by counting the steps of the nanoparticle 
photobleaching. The distribution of photobleaching steps is quantified to obtain the average 
number of proteins per nanoparticle. The photobleaching counts can be obtained by 
ensemble or single-molecule measurements.102
FCS measures the fluctuations of fluorescence intensity due to the Brownian motion of 
fluorescent particles in a small space. The hydrodynamic particle radii (RH) can be 
calculated through the average diffusion time (τD), the diffusion coefficient (D) and the 
Stokes–Einstein relationship. Using this approach, the KD of human serum albumin-
nanoparticle binding (~5.1 μM) and the protein-nanoparticle thickness (~3.3 nm) were 
estimated.103
The binding sites of nanoparticles on a protein can be identified using NMR. 2D [15N-1H]-
Heteronuclear single quantum coherence (HSQC) NMR was used to identify a specific 
binding domain of GNPs on the surface of human ubiquitin. The addition of GNPs changed 
the positions of certain peaks, while others were unaffected (Figure 5), indicating specific 
interactions. In the pre-assigned peak map, the largest chemical shift changes were from the 
NH backbone of Q2, L15 and E18. Based on a combination of the chemical shift changes 
within the protein crystal structure, a domain containing Q2-I3 and L15-E18 was proposed 
to be the specific binding site for GNPs in GNP-ubiquitin interactions.104
The binding sites of nanoparticles on a protein can also by identified using cross-linking 
chemistry and MS. As shown in Figure 6, the peptides located very close to polyacrylic 
acid-coated Fe3O4 nanoparticles in the binding site of human serum albumin (HSA) were 
cross-linked onto the nanoparticle surface with 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride. The attached peptides were identified by protein cleavage 
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followed by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry 
(MALDI TOF-MS). The nanoparticle binding site on HSA was therefore identified. The 
identification of binding sites helps determine the binding specificity and predict possible 
biological consequences of nanoparticle-protein interactions.105
DLS can be used to estimate nanoparticle-protein binding stoichiometry. The adsorption of 
proteins causes a small increase in the dynamic radius of nanoparticles. In one study, the 
adsorption of hexahistidine-tagged cytochrome P450BSβ molecules to the surface of QDs 
was investigated by DLS. The measurements revealed that six P450BSβ molecules bind to 
the surface of each QD.106
3.2.1.2. Measuring Nanoparticle-Protein Binding Kinetics: SPR technology is based on 
the change in the oscillation of surface plasmon waves caused by the adsorption of 
molecules onto a metal surface.107 Using this approach, polymeric nanoparticle-plasma 
protein binding kinetics have been investigated. Nanoparticles are anchored on the gold 
surface of the sensor chip, and proteins are injected to flow over the nanoparticle-modified 
surface.108 A QCM can be used to measure the resonant frequency shift, which can be 
correlated with a mass change at the oscillating quartz surface. Either proteins or 
nanoparticles can be immobilized onto the gold surface on the quartz crystal. The binding 
partner (nanoparticles or protein) is injected and flowed through a flow chamber over the 
quartz surface, and the frequency is monitored.109,110 Using either SPR or QCM, the real-
time and quantitative binding profile can be obtained, and the association and dissociation 
constants can be determined by fitting to the Langmuir adsorption isotherm or Scatchard 
equation.
3.2.2. Chemical Origin of Nanoparticle-Protein Interactions—The interactions of 
nanoparticles with proteins are dominated by many chemical processes. The properties of 
the nanomaterials significantly influence these processes. Next, we discuss the mechanisms 
of interactions between proteins and different nanomaterials.
3.2.2.1. Carbon Nanoparticles: Carbon nanoparticles, such as CNTs, fullerene and 
graphene, contain only sp2 carbons, while nanodiamonds contain exclusively sp3 
carbons.111-114 The uniqueness of sp2 carbon nanomaterials is due to their overwhelming π-
π systems.114 Strong interactions between these materials and proteins are derived from π-π 
stacking, hydrophobic and electrostatic interactions.19,115,116 ENREF 36 Interactions 
between aromatic groups on carbon nanomaterials and aromatic or amine residues in 
proteins play a vital role in binding.117 Therefore, nanoparticle-protein binding events 
depend on the carbon nanoparticles, the nature of proteins and microenvironmental factors, 
such as pH and ionic strength.19,115,118-122 ENREF 38 Charge transfer between CNTs and 
streptavidin has been observed, indicating interactions between the amine groups of the 
protein and the aromatic surface of the CNTs.117 TEM and AFM observations have 
indicated that the bound proteins were found to form well-organized structures on the 
nanotube surface depending on the nanotube’s diameter and the bound proteins (Figure 
7).52,123 CNT-bound proteins generally form multiple layers on the nanotube surface.124 
This property can be used for nanotube debundling, stabilization, separation and protein 
sensing.115,120,125-127 ENREF 40 The bound proteins often undergo changes in structure and 
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activity. Molecular simulation studies have demonstrated that proteins undergo stepwise 
conformational changes after binding to CNTs.128-130 For example, both soybean 
peroxidase and α-chymotrypsin bind to SWNTs; soybean peroxidase retains 30% activity, 
while α-chymotrypsin retains only 1% activity. This difference in activity occurs because 
soybean peroxidase partially maintains its secondary structure after binding, while α-
chymotrypsin completely loses its secondary structure.118 CNTs enhance the rate of protein 
fibrillation by decreasing the lag time preceding nucleation, indicating the potential of CNTs 
to induce amyloid formation, as well as the assembly of novel nanoparticles.131
The interactions of C60 with proteins have been studied using biochemical, structural and 
molecular simulation approaches.132-137 The possible chemical interactions responsible for 
C60-protein binding events include hydrophobicity, surface curvature, π-π stacking, uneven 
charge distribution, site fit and solvent displacement.135 Molecular dynamic studies have 
demonstrated that interactions such as hydrophobicity and π-π stacking represent the 
dominant factors.138 The binding site of C60 on its antibody has been identified using X-ray 
crystallography. C60 binds to the interface of the antibody light and heavy chains.139 The 
binding sites of C60 in human and bovine serum albumin (BSA) and HIV-protease are quite 
similar, but are different from that in the C60 antibody.132 Amino acid-modified C60s can 
penetrate the lipid membrane, bind to the hydrophobic domains of proteins and alter the 
function of membrane-bound enzymes.140
Graphene is another hexagonal carbon nanostructure. In contrast to CNTs and fullerenes, 
graphene consists of planar atomic thin layers.2,141 Because of the sp2 carbon structure, the 
driving forces for interactions between proteins and graphenes are mainly hydrophobicity 
and π-π stacking. Molecular dynamics simulation predicted that human insulin can be 
adsorbed onto graphene surfaces and that some proteins would be destroyed or partially 
destroyed.142 Water-soluble graphene oxide nanosheets (GO) are oxidation products of 
graphene nanosheets. GOs have a stronger serum protein adsorption capability than SWNT 
or MWNT. The thickness of the GO layer increased from ~1.0 nm to 4.0-18.0 nm after 
protein binding.143 The function of proteins adsorbed on the GO surface can be inhibited 
(e.g., the enzymatic activity of chymotrypsin144). The GO-protein binding equilibrium can 
be reached in 30 minutes, and protein adsorption mitigates the cytotoxicity of GO.143
In contrast to sp2 nanostructures, diamond nanoparticles consist exclusively of sp3 bonds. 
These nanoparticles bind protein molecules through hydrophobic interactions and physical 
adsorption and are used in tissue engineering (e.g., immobilization of bone morphogenetic 
protein 2 (BMP-2) to promote bone formation145) or as mass spectrometric matrices.146
3.2.2.2. GNPs: GNPs most likely interact with proteins through electrostatic, hydrophobic, 
and sulfur-gold interactions.23,147-151 GNPs with citrate as a stabilizing agent can bind to 
proteins according to the Langmuir isotherm.151,152 The size of nanoparticles influences the 
mechanism of protein binding. One study demonstrated that electrostatic interaction is the 
major binding force for nanoparticles with a diameter of 16 nm, while hydrophobic 
interaction is the major force for nanoparticles with a diameter of 2-4 nm.148 Because the 
gold surface forms strong bonds with thiol groups in cysteine residues, the GNPs bind BSA 
and heparin-binding growth factors.151,153 ENREF 4 The latter activity may be used to 
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inhibit tumor angiogenesis.154 The perturbation of the conformation and activity of bound 
proteins is influenced by the size and surface properties of the nanoparticles, the 
characteristics of the protein and the ionic strength and pH of the solution.148,155-158 
Cytochrome C is adsorbed onto anionic nanoparticles followed by conformational changes 
and proteolysis.147 Chymotrypsin binds to GNPs and undergoes a two-stage change: fast, 
reversible inhibition, followed by slow, irreversible inactivation.150 The nanoparticle surface 
chemistry can regulate GNP-protein interactions.155,159 Amino acid-modified GNPs can 
also tune the enzymatic activity of bound α-chymotrypsin.159 The nanoparticle size 
influences the denaturation kinetics of BSA on GNPs.157 Negatively charged poly(acrylic 
acid)-conjugated GNPs bind to and induce the unfolding of fibrinogen. The unfolded 
fibrinogen promotes MAC-1 receptor activation and inflammation.160
3.2.2.3. Iron Oxide Nanoparticles: The adsorption of BSA molecules onto magnetic iron 
oxide nanoparticles fits well to the Langmuir isotherm.161 The adsorption kinetics fit to a 
linear driving force mass-transfer model. Similar to other nanoparticles, iron oxide 
nanoparticles also induce protein conformational changes and alter protein activity. Human 
transferrin molecules are adsorbed onto the surface of superparamagnetic iron oxide 
nanoparticles and undergo conformational changes from a compact to an open structure. 
This transformation induces the release of iron.162
3.2.2.4. Quantum Dots (QDs): Electrostatic interactions, sulfur-metal bond formation and 
spatial effects are believed to be major driving forces for QD-protein binding.163-165 CdS 
nanoparticles are trapped in the cylindrical cavity of chaperonin proteins and become 
thermally stable and tolerant to electrolytes.163 The binding between QDs and HSA occurs 
near a protein pocket centered at Lys199.164 Calculations reveal negative enthalpy (ΔH) and 
positive entropy (ΔS) values for this interaction, indicating that electrostatic interactions 
play a major role in the binding reaction. The stoichiometry of bound protein molecules on 
each QD is approximately 6. The bound proteins undergo substantial secondary and tertiary 
structural changes.164 In another study, the electrostatic adsorption of hemoglobin (Hb) to 
CdS nanoparticles was shown to be energetically favorable. Raman spectroscopic results 
indicated that the sulfur atoms of the cysteine residues form direct chemical bonds with the 
CdS QD surface. Although higher structures are disturbed, the spin state of the heme iron is 
not affected.166 In addition to native proteins, denatured BSA molecules also bind to the 
surface of CdTe QDs and form a shell-like complex.167 The protein shell structure results in 
the removal of Te atoms from the CdTe surface and the formation of a thermodynamically 
stable nanostructure. Similar to CNTs, QDs also enhance protein fibrillation.131
3.2.2.5. Silica Nanoparticles: Electrostatic interactions may also be a driving force for 
protein adsorption by silica nanoparticles, as determined by DSC.168 A decrease in ionic 
strength is accompanied by a reduction in protein binding enthalpy, indicating that there is a 
strong electrostatic attraction in silica nanoparticle/lysozyme and silica nanoparticle/RNase 
binding.168 Hydrophobic interactions and hydrogen bonding are also driving forces in silica 
nanoparticle-peptide binding.22 The bound proteins on silica nanoparticles assume a specific 
orientation. The adsorption of human carbonic anhydrase II onto negatively charged silica 
nanoparticles appears to be specific to limited regions at the N-terminal domain of the 
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protein.169 In this study, the orientation of the bound proteins is also pH-dependent. At pH 
6.3, a histidine-rich area around residue 10 is the dominant binding region. At higher pH 
values (e.g., pH 9.3), the protein is adsorbed near a region close to residue 37, which 
contains several lysine and arginine residues. This absorption behavior indicates that 
specific binding may be a result of electrostatic interactions between the positively charged 
areas on the protein surface and the negatively charged silica surface. The binding of protein 
onto nanoparticles occurs in two steps: the rapid formation of a protein-particle complex, 
followed by an irreversible protein conformational change.170 Nanoparticle-induced protein 
conformational changes vary depending on the nature of proteins. Unlike the “hard” (very 
stable) protein carbonic anhydrase II, the “soft” (less stable) protein carbonic anhydrase I 
undergoes a larger structural rearrangement when adsorbed onto silica nanoparticles, as 
shown by NMR.171 The size of silica nanoparticles determines the surface curvature, which 
influences protein adsorption and the stability of the adsorbed proteins. For instance, larger 
nanoparticles cause a greater loss of α helicity and enzymatic activity in bound lysozyme 172 
and induce a greater decrease in the thermodynamic stability of RNase A.173 In another 
study, silica nanoparticles were shown to promote α-helical structures in a designed peptide 
of low helical content in solution.174 Consequently, the protein conformational changes 
altered their cell binding capability and reduced proliferation of human cells.175
3.2.2.6. Polymeric Nanoparticles: The adsorption of proteins onto polymeric nanoparticles 
also depends on the hydrophobicity and surface curvature of nanoparticles. The interactions 
of proteins with N-iso-propylacrylamide/N-tert-butylacrylamide copolymer nanoparticles 
with different monomer ratios and particle sizes demonstrate that proteins tend to bind to 
more hydrophobic nanoparticles by forming a single layer on the surface.176 Surface 
chemistry also influences protein binding. For instance, in dextran phenoxy/poly(ethylene 
oxide) copolymer-modified polystyrene latex nanoparticles, BSA can deform and penetrate 
the poly(ethylene oxide) layer to bind to the nanoparticle surface. In contrast, a densely 
packed dextran phenoxy layer prevents nonspecific adsorption.177 Similar to CNTs and 
QDs, polymer nanoparticles also promote protein fibrillation by enhancing the nucleation of 
protein fibrils from human β2-microglobulin.131 The promotion of fibrillation may be a 
common property for a large number of nanoparticles. Another study concluded that the first 
layer of bound proteins is much more stable than the secondary layer on the nanoparticle 
surface. The first layer was hence called the “hard corona”, indicating nearly irreversible 
binding, and the secondary layer was termed the “soft corona”, indicating greater dynamic 
exchange with the surrounding milieu.178
The above studies demonstrate that protein binding is a nature of all nanoparticles, 
regardless of material. The material origin, size, shape and surface chemistry of 
nanoparticles determine the chemical or physical forces involved in the interactions of 
nanoparticles with proteins. These interactions can be modified through adjusting the 
physicochemical properties of the nanoparticles.
3.2.3. Interactions Between Nanoparticles and Proteomes—Although the 
elucidation of the interactions between nanoparticles and single proteins facilitates an 
understanding of the chemical nature of such interactions, in biological systems, 
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nanoparticles encounter proteomes, not a single protein. Blood and cellular proteomes 
consist of thousands of proteins with diverse functions, sequences, molecular weights, 
isoelectric points, surface hydrophobicities and concentrations. The protein corona 
composition is determined by the thermodynamic and kinetic properties of the interactions 
between the nanoparticles and proteins.108 The selectivity in protein binding is influenced 
by factors such as the size and surface chemistry of the nanoparticles and the properties of 
the proteins.179-182
The binding between polymer nanoparticles and plasma proteins is highly dynamic. 
Abundant yet low-affinity HSA molecules quickly bind to the surface of nanoparticles and 
are soon replaced by the high-affinity and slow-exchanging apolipoproteins AI, AII, AIV 
and E. These proteins remain associated with the particles.108,182,183 Although the formation 
of a protein monolayer is an acceptable model, nanoparticles can also attract additional 
layers of proteins. By analyzing the adsorption of fetal bovine serum proteins onto iron 
oxide nanoparticles by gel electrophoresis and LC-MS/MS, proteins that strongly bind to the 
surface of nanoparticles were identified. These proteins include complement factor H, 
antithrombin, complement factor I, α-1-antiproteinase and apolipoprotein E. These surface-
bound proteins serve as linkers to further bind other serum proteins, such as BSA molecules, 
which adsorb with lower affinity onto iron oxide nanoparticles.184
Like single-protein bindings, proteome binding by nanoparticles is strongly affected by the 
surface chemistry of nanoparticles. Low-density lipoprotein, very-low-density lipoprotein 
and high-density lipoprotein bind strongly to QDs with cholesterol and atheronal-B 
modifications when compared to amine-modified QDs.179 Polyethylene glycol (PEG)-
modified nanoparticles reduce protein binding. PEG chain length and density on polymeric 
nanoparticle surfaces regulate the amount of human plasma protein adsorption but not the 
binding pattern. The main bound proteins identified by 2D polyacrylamide gel 
electrophoresis analyses are albumin, fibrinogen, IgG, Ig light chains and the 
apolipoproteins AI and E. The reduced protein binding on nanoparticles coincides with 
decreased nanoparticle internalization by cells.180 Stepwise increases in PEG density on 
nanoparticle surfaces shift the serum protein binding pattern in addition to the binding 
amount. (Figure 8) An increase in PEG density reduces the internalization of GNPs into 
cells, similar to polymeric nanoparticles.181 ENREF 54 Nanocapsules with longer PEG 
chains and higher PEG density also reduce complement system activation and uptake into 
J774A1 macrophage-like cells.185 The polysaccharide modifications on the surface of poly-
(isobutylcyanoacrylate) nanoparticles reduce plasma protein binding and complement 
system activation.186 Magnetic iron oxide nanoparticles with different sizes and surface 
chemistries bind different serum proteins without changing the protein secondary 
structure.187 The PEG coating on these nanoparticles reduces both cell uptake and 
cytotoxicity. Smaller PEG-coated nanoparticles bind relatively more serum proteins and 
display reduced cellular uptake. The composition of cell culture media also affects protein 
adsorption and cellular effects. Using GNPs as a model, Dulbecco's modified Eagle’s 
medium elicited the formation of a protein corona, while the use of Roswell Park Memorial 
Institute medium resulted in different dynamics with reduced protein coating. Protein-
nanoparticle complexes formed in the latter medium are more abundantly internalized by 
cells and cause greater cytotoxicity than those formed in the former medium.188 The heat 
Mu et al. Page 14













inactivation of serum affects protein corona formation and cellular uptake of protein-
nanoparticles complexes because heating induces changes in serum composition and protein 
conformation.189
3.3. Nanoparticle-DNA Interactions
Nanoparticles bind nucleic acids (e.g., DNA) in biological systems. The features of 
intermolecular forces involved in DNA binding are similar to those involved in 
nanoparticle-protein binding. Such interactions can be exploited for biomedical applications, 
including DNA loading on nanoparticles for gene transfer and siRNA delivery. 
Nanoparticle-DNA interactions depend on the properties of both the DNA molecules and 
nanoparticles.
3.3.1. Determination of Nanoparticle-DNA Interactions—Nanoparticle-DNA 
interactions can be detected through determining complex formation, binding-induced DNA 
conformational changes and DNA degradation.
The binding of DNA molecules to nanoparticles alters the properties of both components. 
For example, binding alters nanoparticle dispersability and surface charge. Such changes can 
be detected with DLS and ζ-potential measurements.53,190,191 The nanoparticle-DNA 
complexes have altered electron absorption spectroscopic patterns, which can also be 
measured using UV-Vis spectroscopy.192-194 DNA binding may increase the near-IR 
fluorescence of some nanoparticles. This increase can be used to monitor the binding 
process.190 DNA molecules, when bound to nanoparticles, can be detected using XPS.20,195 
By enhancing adenine and guanine ring breathing vibrations, surface-enhanced Raman 
spectroscopy (SERS) has been used to monitor DNA binding onto GNPs.196 AFM detects 
subnanometer scale phenomena and is used for the ultrastructural observation of 
nanoparticle-DNA complexes.190,193,197-199 Linear dichroism monitors the differential 
absorption of polarized light parallel and perpendicular to the orientation direction and 
enables the determination of the approximate orientations of the DNA molecules on 
CNTs.200,201
Fluorescence spectroscopy can be employed to determine DNA/nanoparticle binding 
affinity. Because of the weak intrinsic fluorescence emission of DNA, ethidium bromide 
(EB) or the low toxicity dye SYBR® Green is used to label DNA molecules.53,202 The 
resonance light scattering method has been used to detect metal ions and 
biomolecules.203,204 Resonance light scattering from nanoparticles and DNA molecules is 
weak, but the scattering intensity is enhanced dramatically when nanoparticles and DNA 
bind to each other, permitting the quantification of nanoparticle-DNA interactions.191,205 
Real-time polymerase chain reaction (RT-PCR) can be used to amplify short DNA 
fragments attached to nanoparticles to quantify their surface coverage.206 The adsorption 
and desorption processes of nanoparticle-DNA complexes can also be measured using 
electrochemical approaches, such as cyclic voltammetry.207 In some cases, the nanoparticle-
DNA complexes can be isolated by anion exchange chromatography.193
Circular dichroism (CD) can be used to detect DNA conformational changes induced by 
nanoparticles.53,191,197,202,208-213 B-A and B-Z transitions can be identified by the 
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appearance of characteristic CD bands.197,211 NMR provides more detailed structural 
information than CD.208 Conformational information can also be obtained by surface-
enhanced infrared spectroscopy, which measures the vibrational modes of DNA 
molecules.214 The structural stability of DNA can also be measured by its melting 
curve.53,197,206,208,210,212 DNA degradation can be evaluated by gel 
electrophoresis.198,201,208,209,215-217 In addition to experimental approaches, molecular 
simulations can predict nanoparticle-DNA binding patterns and nanoparticle-induced DNA 
conformational changes.218,219
3.3.2. Current Understanding of Nanoparticle-DNA Interactions
3.3.2.1. Carbon Nanoparticles: Due to the large surface area of CNTs, DNA molecules 
bind to the surfaces of nanoparticles almost spontaneously.218 This binding enhances the 
aqueous solubility of CNTs.193,220 Due to the unique shape and electronic properties of 
CNTs, the interaction modes between DNA and CNTs are different than those between 
DNA and other nanoparticles. DNA molecules can adsorb and wrap onto the nanotube 
through π-π stacking and hydrophobic interactions or even insertion into the central 
cavity.190,199,218,219 Such interactions also cause conformational changes in DNA 
molecules.190,197,208,211,214
Both experimental evidence and molecular simulation indicate that DNA molecules form a 
helical structure before wrapping up CNTs.193,199 Optical absorbance measurements have 
revealed that anisotropic hypochromicity results from single-strand DNA/CNT interactions 
through π-π stacking interactions.194 Due to π-π stacking interactions, DNA bases tend to 
orient themselves (Figure 9) facing the tube, as determined by investigating the interactions 
between CNTs and DNA homopolymers.194 Although one study demonstrated that binding 
of CNTs with DNA is independent of DNA sequence,198 the sorting and separation of CNTs 
by DNA has been shown to be affected by DNA sequence.199 The separation of CNTs by 
d(GT)n (n = 10~45) is more efficient than separation by other sequences present in a single-
strand DNA library. DNA molecules with GT-rich sequences wrap individual nanotubes 
more effectively and form a helical structure.199 Linear dichroism revealed that the DNA 
molecules lay flat on the nanotube surface with the backbone wrapping around the nanotube 
at an oblique angle of 45°.200
DNA/CNT binding induces DNA conformational changes. Binding of SWNTs to DNA 
induces B-A and B-Z (Figure 10) transitions.197,211,214,218 The B-Z transition modulates the 
dielectric environment of the SWNTs and decreases their near-IR emission. These changes 
have been detected in whole blood, tissue and living cells.211 SWNTs inhibit DNA duplex 
association and induce telomeric i-motif formation by binding to the 5’-end major 
groove.208 In addition to CNT-induced DNA conformational changes, the binding of 
SWNTs affects DNA hybridization. DNA molecules adsorbed to SWNTs display much 
slower hybridization kinetics than free DNA.190 Pre-adsorption on the SWNT surface causes 
a decrease in the free energy of the DNA, which increases the energy required for the 
conversion of the DNA strands into the transition state. The process can be fitted well with a 
two-step Langmuir model.190 The binding of DNA to CNTs can also alter the optical 
properties of SWNTs. Racemic SWNTs exhibit circular dichroism only when wrapped by 
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DNA molecules. This induced circular dichroism occurs when transition dipole moments of 
optically active electronic transitions in the DNA molecule are coupled to transition dipole 
moments of the SWNTs.213 The altered CD spectra can be used to characterize DNA-
SWNT wrapping.
Other carbon nanoparticles also exhibit strong interactions with DNA molecules. For 
example, graphene oxide nanosheets and fullerene can cleave DNA strands when copper 
ions or visible light is present.209,217 The magnitudes of the binding energy of bases with 
graphene are similar to those found in SWNTs. Interactions are also driven by hydrophobic 
interactions and π-π stacking.221,222 The binding of a DNA duplex to graphene oxide causes 
a partial deformation of the double helix.223 Therefore, a high binding affinity to DNA 
molecules may be a common feature of carbon-based nanomaterials.
3.3.2.2. GNPs: Interactions between GNPs and DNA molecules are mainly driven by 
electrostatic interactions.192,216,224 The formation of a complex between DNA and 
tiopronin-modified GNPs occurs in three steps:53 the first step is the diffusion-controlled 
formation of an external adduct; the second step is the formation of DNA-GNP complex I 
based on their binding affinity; and the third step is the formation of a more compact DNA-
GNP complex II after DNA conformational changes. DNA-GNP interactions are influenced 
by the properties of the DNA and nanoparticles and the microenvironment.202,225 Small 
Au55 clusters (size ~1.8 nm) attach to the major grooves of B-DNA and cause a B-A 
transition. Au55 nanoclusters are then degraded to 13-atom nanoclusters due to shrinkage of 
the major grooves. Au13 nanoclusters and A-DNA ultimately form a wire-like structure.24 In 
another study, GNPs with a diameter of 4.4 nm and coated with 
trimethyl(mercaptoundecyl)ammonium monolayer assembled into a one-dimensional (1D) 
chain along a DNA strand through electrostatic interactions between the cationic 
nanoparticle surface and anionic DNA bases.192 The surface coverage of thiol-capped 
oligonucleotides bound to GNPs decreases from 30 pmol/cm3 to 13 pmol/cm3 when the 
nanoparticle diameter is increased from 13 nm to 30 nm.206 In addition to nanoparticle size, 
nanoparticle surface chemistry, salt concentration and sonication affect DNA/GNP 
interactions.225
In addition to GNP-induced DNA conformational changes, nanoparticles also induce other 
changes in DNA molecules. Nanoparticles promote the relaxation of supercoiled DNA 
under X-ray radiation,226 inhibit hybridization and transcription,20,227 induce double strand 
separation228 and enhance Raman signals from double-stranded DNA molecules.196 These 
altered properties can be employed for DNA detection,229 protection of DNA from DNAase 
I digestion,230 inhibition of the amplification of mismatched primer-template pairs, and 
enhancement of the specificity of allele-specific PCR.231 Interactions between DNA and 
GNP can also be used to build novel nanostructures. For example, the hybridization of 
complementary DNA is used to construct discrete GNP-QD nanostructures.232 Organized 
DNA motifs are used to make ordered GNP arrays.233
3.3.2.3. Other Nanoparticles: Other nanoparticles also interact with DNA molecules 
through electrostatic and hydrophobic interactions. Linear QD chains are formed along 
double-stranded DNA through electrostatic interactions.234 Plasmid DNA bound to the QD 
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surface can be released by intracellular glutathione (GSH) during transfection.195 Calf 
thymus DNA molecules are adsorbed onto zirconia nanoparticles.207 Titanium oxide 
nanoparticles are widely used in sunscreen products, and their potential toxicity has received 
considerable attention.235 These nanoparticles bind to DNA molecules and cause DNA 
degradation due to the generation of hydroxyl radicals on the nanoparticle surfaces.236,237 
This DNA damages induce oxidative stress in living cells and animals.238 Similar to 
titanium oxide nanoparticles, copper nanoparticles cause DNA degradation through the 
generation of singlet oxygen.239 Ag and Pt nanoparticles inhibit DNA hybridization by 
disrupting hydrogen bonding between DNA double strands. This inhibition is weakened as 
the nanoparticle size increases.20 Binding of calf thymus DNA to Ag nanoparticles induces 
conformational changes in DNA molecules.210
Both cationic and anionic polymer nanoparticles bind DNA molecules and cause DNA 
conformational changes.191,212 Cationic poly-L-lysine-modified silica nanoparticles inhibit 
DNA transcription, and this inhibition is size-dependent (Figure 11). DNA chains are 
adsorbed irreversibly to the surface of nanoparticles (40 nm), inhibiting polymerase 
function. However, smaller nanoparticles (10 nm) form chains along DNA strands and 
might eventually dissociate from the DNA strand. This allows the DNA molecules to 
become accessible to the polymerase, and transcription proceeds.240
The interactions between nanoparticles and DNA molecules share some common features 
with nanoparticle-protein interactions. In both cases, biomolecules are adsorbed to the 
nanoparticle surface, and the binding induces conformational changes in these molecules. 
Nanoparticle-DNA interactions can also be used to develop advanced nanoparticle-DNA 
hybrids to control cellular processes for biomedical and biosensing purposes.
3.4. Adsorption of Crucial Small Molecules by Nanoparticles
Due to their high surface energy, nanoparticles also adsorb various small molecules in 
biological systems. These molecules include but are not limited to carbohydrates, vitamins, 
hormones, amino acids and nucleic acid bases.54,241-245 These small molecules normally 
play essential roles in cell signaling and cell physiology. A sudden depletion of these 
molecules may influence proper cellular functions and cause toxicity.54,244,246 Small 
molecules are adsorbed onto nanoparticles through molecular interactions, such as 
hydrophobic, π-π stacking and electrostatic interactions.54,247 Although the chemical bases 
of nanoparticle/protein interactions and nanoparticle/amino acids interactions are similar, the 
latter is simpler, faster and does not involve conformational alterations.
SWNTs adsorb various amino acids (e.g., Arg, His, Met, Phe and Tyr), vitamins (folate, 
riboflavin and thiamine) and phenol red in cell culture media.54 An analysis of the structures 
of the adsorbed molecules indicates that π-π interactions and electrostatic interactions are 
likely the driving forces for adsorption. The SWNT-induced depletion of amino acids and 
vitamins in cell culture medium reduces cell viability. Spectroscopic studies have revealed 
that both SWNTs and MWNTs affect the cell culture medium in this manner.244,248 A study 
of the adsorption of folic acid and vitamin B1 by carbon fibers with modified nanopores 
revealed that the pore structure and surface modifications influenced the adsorption capacity 
and adsorption rate.245
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Computational chemistry reveals that the curvature of nanoparticles and the polarizability of 
amino acids determine binding strength.247 Doping the carbon surface with calcium atoms 
results in a dramatic enhancement of binding of collagen amino acids (Gly, Pro and Hyp) to 
graphene. Electronic charge transfers from the calcium atoms (donor) to graphene (acceptor) 
and the carboxyl group of the amino acid (acceptor) may contribute to this enhancement.249
4. NANOPARTICLE-CELL INTERACTIONS
The cell is the elemental unit of all living organisms. Nanoparticles perturb living systems 
by interacting and altering live cells. Such perturbations occur at various levels. 
Nanoparticles are first adsorbed to the cell surface and are then internalized. As the 
nanoparticles are endocytosed and transported within cells, the cells undergo structural and 
functional changes. Some crucial processes, such as oxidative balance, are perturbed. 
Eventually, global alterations occur that involve cell signaling, genomic, proteomic and 
metabonomic processes.
4.1. Cellular Uptake and Intracellular Transport of Nanoparticles
Because of their sizes and surface properties, nanoparticles can enter various organisms and 
cells, including mammalian cells, plant cells, bacteria, fungi and viruses.250-254 These 
processes can be energy-dependent intake or energy-independent insertion.255,256 The 
former is also referred to as endocytosis, a process by which cells take up molecules or 
particles by engulfing them.257 Nanoparticles enter cells by taking advantage of various 
known endocytotic pathways, such as clathrin-mediated endocytosis, caveolae-mediated 
endocytosis, phagocytosis and macropinocytosis.256,258-261 Direct penetrations occur for 1D 
nanostructures or strongly positively charged nanoparticles.255,262 After entering cells, 
nanoparticles may localize in endosomes, lysosomes, the cytoplasm, mitochondria, the 
endoplasmic reticulum or the nucleus, depending on the nature of the 
nanoparticle.256,258-261,263-266 Various imaging techniques have been developed to monitor 
the cell uptake process, in addition to conventional TEM and confocal laser scanning 
microscopy (CLSM) analyses.267,268 For example, X-ray fluorescence microscopy is used to 
determine chemical element distribution of nanoparticles in cell.269 Magneto-photo-acoustic 
imaging permits the differentiation of membrane-adhered or endocytosed nanoparticles.270 
Dynamic colocalization microscopy permits the spatio-temporal characterization of 
internalized nanoparticles.271 Raman spectral imaging maps vibrational bands of 
nanoparticles in live cells in the absence of an external label.272 Atomic force microscopy 
(AFM) measures the force between nanoparticles and the cell surface, indicating receptor 
binding and binding strength.273-275
4.1.1. Kinetics and Thermodynamics of the Cellular Uptake of Nanoparticles—
The endocytosis of nanoparticles is a dynamic process, and the endocytosis and exocytosis 
processes eventually reach thermodynamic equilibrium. Endocytosis likely involves at least 
two steps: binding of the nanoparticles to the cell surface, followed by the internalization of 
the nanoparticles into cells (Figure 12).276 Binding parameters derived from the binding of 
anionic magnetic nanoparticles to RAW macrophages and HeLa cells reveal that 
macrophages and tumor cells behave equally with respect to cell surface binding, although 
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they differ with respect to internalization capability. The adsorption onto the cell surface is a 
slow step, and internalization is fast.277-279 Nanoparticles are eventually exocytosed from 
living cells. The exocytosis rate of SWNTs is reported to closely match their endocytosis 
rate with negligible temporal offset.280 However, the uptake of dye-labeled polystyrene 
nanoparticles is reported to increase with time and be essentially irreversible. The 
fluorescence signal decreases when cells divide.268 This controversy suggests that cell 
uptake kinetics may depend on both nanoparticle properties and cell type. The endocytosis 
of nanoparticles is also under thermodynamic control. Thermodynamic studies have 
revealed that adhesion strength governs receptor-mediated cell uptake. Endocytosis is 
determined by the enthalpic and entropic limits of the adhesion strength.281 Based on the 
energy requirements for a receptor-mediated uptake process, the optimal size of 
nanoparticles is 25~30 nm.282 When the nanoparticles are too small (less than 20 nm), 
endocytosis is limited because the adhesion energy is too low to compensate for the bending 
energy of the cell membrane. When the nanoparticles are too large (greater than 60 nm), the 
free receptors on the cell membrane are depleted, and nanoparticles may be only partially 
wrapped without endocytosis. Here, size refers to the apparent size after aggregation. A 
further understanding of the kinetics and thermodynamics of the cellular uptake of 
nanoparticles will assist future nanoparticle design and applications.
4.1.2. Determinants of the Cellular Uptake of Nanoparticles—Many 
physicochemical and biological factors govern the cellular uptake of nanoparticles. These 
factors include the size, shape, surface chemistry, surface charge and mechanical properties 
of nanoparticles, as well as cell type. The combination of these factors affects the cell 
surface binding strength,273,275 cellular entrance route,283,284 uptake amount278,285-290 and 
intracellular distribution.283,291,292 SWNTs with lengths of 100-200 nm can be internalized 
into cells through clathrin-coated pits. SWNTs with lengths of 50-100 nm enter cells 
through caveolae-mediated endocytosis, and some can enter the nucleus. The shortest (less 
than 50 nm) SWNTs can enter cells through direct insertion, which is energy 
independent.283 Studies of GNPs (4-17 nm) in HeLa cells have revealed that the uptake 
force increases with the size of the nanoparticles.275 The shape of the nanoparticle may also 
play a role. Gold nanospheres enter fibroblasts and tumor cells more efficiently than 
nanorods,293-295 while nanorods are internalized more efficiently than nanospheres in blood 
phagocytes.296 Particle replication in non-wetting template (PRINT) nanoparticles with a 
higher aspect ratio enter HeLa cells more readily than those with a lower aspect ratio.297 The 
surface charge on nanoparticles can play a significant role in cellular uptake. Due to the 
presence of phosphate groups on lipids, cell membranes are negatively charged. 
Nanoparticles with positive charges display strong interactions with cells compared with 
those with negatively charged or neutral surfaces.292,298
Furthermore, the structure, density and distribution of surface chemical groups all play 
significant roles in determining the cellular uptake of nanoparticles. For peptide-
functionalized GNPs, an aromatic structure at the end of the peptide enhances their cellular 
uptake.290 A higher density of oligonucleotide loading on the surface of GNPs generates 
higher cellular uptake, while a higher density of PEG reduces GNP uptake.181,287 GNPs that 
have striations on the surface with alternating anionic and hydrophobic groups can penetrate 
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the plasma membrane without disrupting it.299 The nanoparticle surface ligand induces 
protein corona misfolding and therefore indirectly enhances cellular uptake.300 A molecular 
simulation study has proposed that the effective surface charge density determines cell 
uptake.301 An experimental study of a surface-modified GNP array indicated that the 
effective surface charge density determines the electrostatic interactions between the 
positively charged nanoparticles and the negatively charged cell membrane (Figure 13).302
Shape is another significant factor in the cellular uptake process. For 1D nanotubes, the 
uptake process is spontaneous when the orientation favors insertion, while 2D nanosheets 
prefer to adhere to the cell surface.255,303 A nanosphere and nanodisk cell uptake 
comparison study demonstrated that nanodisks mainly adhere to the cell surface, while 
nanosphere are easily internalized into cells (Figure 14).25 A similar conclusion was reached 
in a subsequent study. Nonspherical polymeric nanoparticles exhibit reduced cellular uptake 
compared to their spherical counterparts. The larger average curvature radius of adsorbed 
non-spherical particles may be responsible for this difference.304 However, 1D 
superparamagnetic iron oxide nanoworms showed enhanced tumor-targeting efficiency 
compared to spherical nanoworms.305 This controversy indicates effects of nanoparticle 
shape on cell uptake are material-dependent.
The mechanical properties of nanoparticles also influence the rate, route and amount of 
cellular uptake.306,307 Soft nanoparticles enter cells through macropinocytosis, while stiff 
nanoparticles enter through clathrin-mediated endocytosis. Nanoparticles with an 
intermediate stiffness have multiple internalization routes.306 The aggregation and 
sedimentation of nanoparticles in physiological environments also impacts cellular uptake. 
More nanoparticles are taken up in an upright cell culture configuration than in an inverted 
one, and nanoparticles with faster sedimentation rates display greater differences in uptake 
between the two configurations, suggesting that sedimentation needs to be considered for 
cellular uptake studies of heavy or large nanoparticles.278,308,309 The different protein 
binding properties of nanoparticles often indicate different nanoparticle-cell 
interactions.287,293,309 The pericellular matrix enhances the retention and cellular uptake of 
nanoparticles, due to the restriction and deceleration of diffusion by the entrapment and 
accumulation of nanoparticles.310 In summary, multiple factors collectively determine the 
cellular uptake of nanoparticles and their subsequent bioactivity in cells.
4.2. Cellular Substructural and Functional Alterations by Nanoparticles
Nanoparticles are translocated to different compartments in live cells and may interact with 
relevant subcellular structures and affect their function. Cell membranes, ion channels, the 
cytoskeleton, mitochondria and the nucleus have all been reported to be affected by 
nanoparticles.
4.2.1. Nanoparticle-Induced Cell Membrane Disruption—The cellular uptake of 
nanoparticles results in the disruption of the plasma membrane. Membrane disruption likely 
involves several physicochemical interactions. Electrostatic interactions of positively 
charged nanoparticles with negatively charged groups on the membrane surface alter cell 
membranes. Membrane penetration of positively charged nanoparticles into the cytoplasm 
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causes the formation of holes within 1~100 ms, followed by a slow resealing in tens of 
seconds.311 Interactions between positively charged nanoparticles with negatively charged 
membrane also causes membrane depolarization and perturbation of membrane potential. 
Furthermore, an increase in [Ca2+] influx inhibits cellular proliferation.312 Membrane 
disruption of red blood cells and perturbation of their hemolytic activity by amorphous and 
mesoporous silica nanoparticles have been attributed to silanol groups that are accessible to 
the membrane.313 Nanoparticle-induced generation of ROS may also cause membrane 
damage. A water-soluble fullerene suspension disrupts cellular functions through lipid 
peroxidation by ROS. Upon addition of an antioxidant, the oxidative damage can be 
completely prevented.314 Nanoparticle shape may also serve a role in membrane 
perturbation. Needle-shaped nanoparticles, rather than sphere or flat nanoparticles, cause a 
transient disruption of the endothelial cell membrane.315 Stimulations such as near infrared 
(NIR) radiation cause cavitation of the membrane, followed by an increased influx of [Ca2+] 
and a degradation of the actin network.316 By expanding our understanding of the various 
mechanisms of interactions between nanoparticles and the cell membrane, reduction of 
membrane disruption will be achieved through the regulation of size, shape, surface 
geometry, surface charge and surface chemistry.46,313,317,318
4.2.2. Ion Channel Inhibition by Nanoparticles—Ion channels consist of pore-
forming proteins that help establish and control a small voltage gradient across the cell 
membrane.319 When nanoparticles reach the cell surface, they may affect ion channel 
function by interacting with the extracellular domains of ion channel proteins. SWNTs 
reversibly block the K+ channel in a diameter-dependent manner, most likely by interacting 
with extracellular domains of the channel.320 In contrast to pristine SWNTs, SWNTs 
modified with 2-aminoethylmethane thiosulfonate inhibit the K+ channel irreversibly, 
suggesting possible bonding between functional groups on SWNTs and the cysteine groups 
in ion channels.321 Carboxylated MWNTs suppress the K+ channel in PC12 cells without 
induction of ROS.322 Molecular simulations indicate that there are multiple C60 binding 
sites on K+ channels. The energetically favorable bindings between C60 and K+ channels 
cause ion channel inhibition and cytotoxicity.323 Although direct interactions between 
nanoparticles and ion channels are observed, impurities may also perturb channel proteins. 
Contamination with yttrium, which is used as a catalyst in the production of CNTs, has been 
shown to inhibit ion channels.324 Thus, nanoparticle-ion channel interactions must be 
studied with care.
4.2.3. Cytoskeleton Alterations by Nanoparticles—The cytoskeleton maintains the 
cell shape and serves significant roles in intracellular transport, force generation, cell 
motility and division.18 The internalization of nanoparticles results in direct or indirect 
cytoskeletal alterations. The loss of proper cytoskeletal function further leads to reduced cell 
motility, division and proliferation.325-329 SWNTs induce actin bundling in both isolated 
actin filaments and HeLa cells. This induces actin-related cell division defects and retards 
cell proliferation. A weak binding enthalpy between SWNTs and actin filaments has been 
speculated to arise because both structures are anisotropic and similar in size. Such 
interactions induce dramatic anisotropic actin bundle formation both in cells and ex vivo.325 
Nanoparticles may also affect the cytoskeleton through indirect interactions. Surface-
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modified iron oxide nanoparticles and gelatin nanoparticles cause a reorganization of the F-
actin and β-tubulin cytoskeletons in human fibroblasts after endocytosis. Because the actin 
cytoskeleton plays important roles in receptor-mediated endocytosis, the different 
nanoparticle-induced alterations in cytoskeleton organization may indicate different 
mechanisms of internalization.327,328 Gold nanorods coated with 
hexadecyltrimethylammonium bromide cause actin aggregation and β-tubulin redistribution 
in the cytosol. Such effects reduce micromotion (fluctuations in cell shape) in MDCK-II 
kidney cells. Coating of nanorods with PEG diminishes such perturbations.326 High 
concentrations of surface-modified iron oxide nanoparticles affect cytoskeleton and focal 
adhesion formation and maturation. The reduced expression and decreased activity of focal 
adhesion kinase in turn alters the actin cytoskeleton. Large endosomes that trap 
nanoparticles may also affect the normal localization of actin fibers and disrupt the actin 
cytoskeleton through steric hindrance.329
4.2.4. Mitochondrial Alterations by Nanoparticles—Mitochondria serve as “cellular 
power plants” by supplying chemical energy (ATP) to cells.18 They are also involved in a 
range of other processes, such as signaling and cell differentiation. Nanoparticles enter the 
mitochondria and may affect their functions.330-333 SWNTs have been identified inside 
mitochondria.333 GNPs (3 nm) enter mitochondrial intermembrane spaces through voltage-
dependent anion channels.334 The direct interaction of nanoparticles with mitochondria has 
been detected using SERS. SERS revealed that GNPs (13 nm) may bind to proteins, lipids 
and carbohydrates present on the mitochondrial membrane in live cells and in isolated 
mitochondria. The bands at 886, 875 and 1070 cm−1 are due to C-C and PO2− vibrations. 
Changes in these bands indicate interactions between nanoparticles and membrane lipids. 
However, these interactions do not cause damage to the mitochondria.331 GNPs with a much 
smaller size (1.4 nm) cause indirect damage by increasing the permeability of the inner 
mitochondrial membrane through the generation of oxidative stress.330
4.2.5. Nuclear Alterations by Nanoparticles—The nucleus maintains the integrity of 
genes and controls cellular activity cells by regulating gene expression. The nuclear 
structures include the nuclear envelope, which consists of a double lipid bilayer, the nuclear 
lumina, which consists of intermediate filaments and membrane-associated proteins, the 
chromosome, which consists of DNA and histones, and the nucleolus, which consists of 
rRNA, rDNA and proteins.49 Because the nuclear envelope keeps many macromolecules 
from entering the nucleus, nanoparticles entry into the nucleus is limited unless the 
nanoparticles are extremely small (< 5 nm) or engineered with nuclear targeting 
molecules.335-338 Unmodified QDs (3.2 nm) are able to accumulate in the nucleus and 
exhibit strong affinity to core histones and histone-rich cell organelles. Histone binding is 
driven by electrostatic interactions between negatively charged QDs and positively charged 
core histone proteins. The interaction causes a redshift of the steady-state photoluminescent 
emission of the QDs and a decrease in the fluorescence lifetime.335 GNPs (2.5 nm) may 
disturb the decondensation of nuclear chromatin in mouse sperm, indicating their potential 
spermatotoxicity. Such effects are likely driven by interactions between GNPs with DNA in 
the nucleus.337 The elucidation of nanoparticle-nucleus interactions provides crucial insight 
into the biological activity of nanoparticles; however, further investigation is still warranted.
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4.3. Oxidative Stress and Nanoparticles
Cells maintain a homeostatic oxidative state and counterbalance external stimuli-induced 
oxidative stress through several regulation mechanisms.339 When these regulating 
mechanisms are overwhelmed, the excessive ROS or reactive nitrogen species (RNS) can 
damage cellular components, affect biomolecule function and ultimately induce cell death 
through apoptosis or necrosis. Nanoparticles may affect the cellular oxidative state in 
various ways. The generation of ROS in cells is considered a major factor in nanoparticle-
induced cytotoxicity.340 However, nanoparticles with reductive properties may act as free 
radical scavengers to remedy oxidative damage in cells and tissues.341
4.3.1. Oxidative Stress Induced by Nanoparticles—The production of nanoparticle-
induced ROS is triggered by electronically active nanoparticle surfaces, photoactivation, 
impurities, the dissolution of metal ions and the interactions of nanoparticles with 
biomolecules.342,343 Nonfluorescent dichlorofluorescin can be oxidized to fluorescent 
dichlorofluorescein inside the cell by various oxidants, and this reaction can be used to 
detect the total oxidative level in live cells.344 ROS generation can also be measured by free 
radical content, GSH level, mitochondrial membrane potential, stress-related gene/protein 
expression, microarray and stress-specific reporter assays.330,340,345-349
Most nanoparticles cause oxidative stress. Although the outcome is similar, the mechanisms 
may be material-dependent. First, GNPs with a diameter of 1.4 nm induce oxidative stress 
and reduce intracellular antioxidant levels. The oxidative stress causes mitochondrial 
damage, an upregulation of stress-related genes and cell necrosis.330 The generation of ROS 
by GNPs upon short-term (4 h) exposure can be counterbalanced by cells; however, longer 
exposure (48 h) can overwhelm antioxidant defenses.350 GNPs also catalyze nitrogen 
monoxide (NO) production from endogenous S-nitrosothiols in serum through the formation 
of Au-thiolate on the surface of nanoparticles.342 Second, TiO2 nanoparticles, which are 
widely used in cosmetics, cause oxidative stress with or without light activation. TiO2 
nanoparticles absorb UV light and catalyze DNA damage in human cells.238 In the dark, 
TiO2 nanoparticles induce ROS generation, a decrease in GSH, upregulation of stress-
related genes, activation of JNK and P53 and apoptosis.351,352 TiO2 nanoparticles generate 
O2· in sunlight and HO· free radicals in the dark.353 Third, carbon black (CB) nanoparticles 
induce oxidative stress by producing highly diffusible 4-hydroxynonenal. This species 
mediates cytotoxicity through the formation of 4-hydroxynonenal-protein adducts and GSH 
modification.354 CB nanoparticles enhance the oxidative stress induced by Fe2O3 
nanoparticles in cell culture through co-exposure. However, surface-oxidized CB 
nanoparticles have no such effects, indicating that the oxidative stress is mediated by the 
surface reactivity of CB.348 Fourth, CNTs induce ROS-related inflammasome activation.355 
Metallic impurities from the CNT synthesis process, if present, may be responsible for the 
generation of oxidative stress.356 Surface chemistry modifications by PEG reduce ROS and 
cytotoxicity.357 5). Fullerene (C60) causes membrane damage and cytotoxicity through ROS 
generation and lipid peroxidation. An antioxidant, L-ascorbic acid, completely prevents such 
oxidative damages.314 6). Other nanoparticles, including ZnO, silica, polystyrene, nickel 
ferrite, silver and nano-Co, have also been reported to induce oxidative stress, mitochondrial 
damage and apoptosis.346,347,358-361
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A nanoparticle’s potential to generate oxidative stress depends on the nature of the 
materials. At the same dose, different nanomaterials cause different levels of oxidative 
stress. For example, ZnO, CuO and CdS nanoparticles generate a higher level of ROS than 
that of TiO2, MgO, SiO2, CNTs and Fe3O4 nanoparticles.362-366 CeO2 can even protect cells 
from oxidative damage.362 Due to the significance of nanomaterials’ intrinsic properties, a 
predictive paradigm for oxidative stress has been developed based on metal oxide 
nanoparticle band gaps.367 Critical physicochemical effectors are discussed below.
The crystal structure of nanoparticles appears to play a role in ROS generation. Rutile TiO2 
nanoparticles cause the generation of ROS and cell apoptosis, while anatase TiO2 
nanoparticles induce necrosis with reduced ROS generation.368 The size and surface area of 
nanoparticles affect ROS generation. Smaller nanoparticles with larger surface areas 
generate much more ROS than larger nanoparticles.369-371 Surface chemistry can regulate 
oxidative stress generation. Cellular ROS generation by surface-modified silicon 
nanoparticles occurs in the following order: positively charged > neutral > negatively 
charged.372 Surface-modified ZnO nanoparticles generate ROS in the following order: 
uncoated > oleic acid coated > poly(methacrylic acid) coated > protein coated.373 
Nanoparticles with hydrophobic molecules on the surface cause oxidative stress in the cell. 
GNPs coated with longer hydrophobic alkyl chains cause much more ROS generation and 
cytotoxicity than those with shorter hydrophobic chains.374 PEG modification on the surface 
reduces oxidative stress caused by SWNTs.357 Some environmental factors may impact 
cellular ROS production. For instance, exposure to light enhances the generation of ROS in 
cells incubated with TiO2 nanoparticles.364 Fe2O3 or CB nanoparticles alone do not cause 
cellular oxidative stress. However, the co-application of these nanoparticles induced a two-
fold increase in the oxidation of cellular proteins. Fe2O3 nanoparticles in endosomes or 
lysosomes are acidified to release Fe3+ ions, which do not generate hydroxyl radicals in the 
presence of H2O2. However, CB nanoparticles reduce Fe3+ ions to Fe2+ ions. Fe2+ ions can 
permeate the vesicle membrane, take part in the Fenton reaction and induce protein 
oxidation.375 In addition to these physicochemical factors, cells from different organs have 
different capabilities of internalizing nanoparticles and resisting oxidative stress.376
4.3.2. Reduction of Oxidative Stress by Nanoparticles—Several nanoparticles have 
free radical scavenging capabilities, which originate from their chemical structures. These 
effects may be potentially applied in antioxidative therapy. Cerium oxide (ceria) 
nanoparticles, fullerene and its derivatives, CNTs and heavy metal (Au and Pt) nanoparticles 
have been reported to reduce ROS through various mechanisms.341,377-386
Ceria nanoparticles inhibit inflammatory mediator production and reduce cell apoptosis. 
These nanoparticles protect rats against oxidative damage by scavenging free 
radicals.378,381,384 When ceria nanoparticles are doped with samarium, which decreases 
Ce3+ without affecting the oxygen vacancy (defect in oxides) contents, their antioxidant and 
anti-apoptotic abilities are reduced. This decrease indicates that the Ce3+/Ce4+ redox 
reaction and not oxygen vacancy is responsible for the antioxidant activity of ceria 
nanoparticles.381 Fullerene and its derivatives have the ability to quench superoxide 
radicals.377,379 CNTs are able to scavenge free radicals and retard the oxidation 
reaction.380,385 Doping of boron on CNTs enhances the efficiency of radical scavenging, 
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indicating that electron affinity may be responsible for the effect. Au and Pt nanostructures 
have also been reported to display antioxidant activities.382,383,386 Pt nanoparticles exhibit 
anti-oxidant activity by scavenging O2·
−
 and HO• with a second-order reaction rate.382 Au- 
and Pt-supported nanodiamonds exhibit a high antioxidant activity, as indicated by their 
peroxidase activity and the ability to trap carbon radicals.383 Apoferritin-coated Pt 
nanoparticles enter cells through receptor-mediated endocytosis, decrease hydrogen 
peroxide-induced oxidative stress and reduce cytotoxicity.386
4.4. Nanoparticle-Induced Systematic Cellular Biochemical Perturbations
Cells have complex biochemical networks that maintain homeostasis during proliferation, 
differentiation and apoptosis. Any extrinsic factors, such as nanoparticles, may interfere 
with these processes. Therefore, understanding nanoparticle-induced cellular biochemical 
perturbations to elucidate the chemical mechanisms of nanoparticle-biological system 
interactions is imperative.
4.4.1. Perturbation of Cell Signaling Pathways by Nanoparticles—Nanoparticles 
perturb many cellular signaling pathways. These pathways are involved in important 
biological processes that determine cell fate. The delineation of these mechanisms will 
facilitate an understanding of the cytotoxicity of nanoparticles and the development of safe 
nanomedicines and nanomaterials.
4.4.1.1. Mitogen-Activated Protein Kinase (MAPK) Signaling: MAPK signaling is a 
significant regulatory mechanism in eukaryotic cells. The MAPKs are serine/threonine-
specific protein kinases that respond to external stimuli, such as mitogen, heat shock and 
oxidative stress. The MAPK signaling pathway regulates cell proliferation, apoptosis, 
morphogenesis, cell cycle and immunity.387
There are three groups of kinases in MAPK signaling. The first group, extracellular signal-
related kinase (ERK), is activated by growth factors, mitogen and G protein coupled 
receptors (GPCRs). Carbon nanoparticles activate Erk1/2 in multiple cell lines.388 ERK is 
also activated by silica and iron oxide nanoparticles.389,390 Activation of Erk1/2 by iron 
oxide nanoparticles promotes neurite outgrowth in PC12 cells.390 The second group, p38 
MAPK, and the third group, JNK, are activated by stress, GPCRs and inflammatory 
cytokines. GNPs can promote osteogenic differentiation through activation of p38 MAPK.21 
TiO2 nanoparticles activate JNK and p53 in neuronal cells and cause G2/M cell cycle arrest 
and apoptosis.351 Silica nanoparticles activate p38 and JNK and reduce cell viability.391 Not 
all nanoparticles activate MAPK signaling. Carboxyl-modified fullerene nanoparticles enter 
oxidative stress-damaged cerebral microvessel endothelial cells, maintain cell integrity and 
inhibit apoptosis. Such effects are the result inhibiting the JNK pathway by nanoparticles.392
4.4.1.2. Nuclear Factor Kappa B (NF-κB) Pathway: The NF-κB pathway is an important 
cellular signaling pathway in response to external stimuli. Under normal circumstances, NF-
κB forms a stable complex with IκB in the cytoplasm. When cells are exposed to stimuli, 
such as stress, free radicals or irradiation, the kinase IKK is phosphorylated (activated) by 
receptors. The activated IKK subsequently phosphorylates IκB. Phosphorylated IκB 
Mu et al. Page 26













undergoes ubiquitous degradation, and NF-κB is released and translocated to the nucleus to 
initiate transcription of inflammatory factors.393 Silver nanoparticles, CNTs, silica 
nanoparticles, TiO2 and double hydroxide (Mg(OH)2 : Al(OH)3 1:1) nanoparticles have 
been reported to activate NF-κB signaling and induce the generation of pro-inflammatory 
cytokines including COX-2, TNF-α, IL-6, IL-12 and inducible nitric oxide 
synthase.47,389,394-398 The chemical basis for the activation of NF-κB signaling by different 
nanoparticles is that all of these nanoparticles generate ROS in cells. The activation of NF-
κB finally leads to a reduction of cell proliferation, inflammation and apoptosis. Surface 
modifications on MWNTs direct the receptor recognition from mainly mannose receptors to 
scavenger receptors. The activation of NF-κB through the mannose receptor is alleviated, 
and the immunotoxicity of MWNTs is reduced.47 This study demonstrates that activation of 
cell signaling by nanoparticles can be regulated through modulating receptor recognition 
events by surface chemistry modifications.
4.4.1.3. DNA Damage and Repair: The cellular ROS generated by nanoparticles may 
cause DNA damage and activate DNA repair signals.399 Such damage may induce G2/M 
cell cycle arrest, apoptosis, mutagenesis and tumorigenesis.400-404 Therefore, an 
understanding of nanoparticle-induced DNA damage and its repair is critical. MWNTs 
increase the expression of the base excision repair protein OGG1, the double strand break 
repair protein Rad 51, the phosphorylation of p53 by the checkpoint protein kinase ChK2, 
the phosphorylation of histone H2AX at serine 139, and SUMO modification of XRCC4 (in 
response to DNA double-strand breakage) in mouse embryonic stem cells.402 Similarly, 
nanodiamonds and silver nanoparticles also induce DNA damage, as demonstrated by 
increased expression of OGG1 and Rad51 and phosphorylation of p53 and H2AX.400,401,403
4.4.1.4. Bone Morphogenetic Protein (BMP) and Transforming Growth Factor beta 
(TGF-β) Signaling: BMP receptors belong to the TGF-β receptor superfamily.405 CNTs 
suppress BMP signaling pathways and affect cell function (Figure 15).406-408 Suppression of 
BMP signaling reveals a non-apoptotic mechanism for the perturbation of cell proliferation 
by CNTs. A global examination of gene expression and Western blotting revealed that the Id 
(inhibitor of DNA binding) genes and proteins are suppressed by SWNTs and MWNTs. Id 
genes are direct targets of Smad-dependent BMP receptor signaling through activation of 
Smad 1/5/8 proteins. The activated Smad proteins translocate into the nucleus to initiate 
transcription. The phosphorylation and nuclear translocation of Smad 1/5/8 are inhibited by 
CNTs. Id genes and proteins are subsequently inhibited. The inhibition of the Id protein 
negatively regulates the cell cycle transition from G1 to S phase and cell proliferation.408 A 
further study revealed that the suppression of BMP signaling is due to binding of CNTs to 
BMP receptor type II (BMPR2) but not BMP receptor type I or the BMP ligand.406
BMP regulates a class of bHLH transcription factor proteins. Id proteins are also bHLH 
proteins but lack the DNA binding domain. Id proteins function as negative regulators of 
transcription. This regulation is significant in cell differentiation, tumorigenesis and 
apoptosis. Suppression of BMP signaling in mesenchymal stem cells leads to inhibition of 
proliferation, myogenic differentiation and reduced apoptosis. Surface chemical 
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modifications of CNTs can tune cell differentiation to different levels through the regulation 
of CNT/BMPR2 binding and BMP signaling.406
Graphene nanosheets activate MAPK and TGF-β signaling pathways in murine RAW 264.7 
macrophages. Graphenes cause an increase in cellular ROS and the activation of 
phosphorylation of ERK, JNK and P38, indicating the activation of MAPK signaling. 
Furthermore, the expression of TGF-β receptor mRNA and phosphorylation of Smad2 are 
also enhanced, indicating the activation of TGF-β signaling. The ROS and activated TGF-β 
signaling pathways further induce cellular apoptosis.409
4.4.1.5. Other Signaling Pathways: GNPs bind to heparin-binding growth factors but not 
to non-heparin-binding growth factors and selectively inhibit heparin-binding growth factor-
induced cell proliferation. This interaction is due to direct binding of gold surfaces with 
sulfur or amine groups present in the heparin-binding domain. The inhibition of heparin-
binding growth factors causes a decrease in vascular endothelial growth factor (VEGF)-165-
induced cell proliferation in vitro and angiogenesis in vivo.153,154 GNPs with a poly(acrylic 
acid) coating selectively bind fibrinogen and induce protein unfolding to expose the C-
terminus of the γ chain. The newly exposed epitope interacts with the Mac-1 receptor and 
activates its signaling. Mac-1 activation induces the release of inflammatory cytokines, 
which is an alternative mechanism for the inflammatory response of cells to 
nanoparticles.160 Silver nanoparticles suppress glial cell line-derived neurotrophic factor 
signaling in spermatogonial stem cells and reduce cell proliferation. This inhibition may be 
due to interactions between nanoparticles and Fyn protein, a kinase in glial cell line-derived 
neurotrophic factor signaling.410 Graphene oxide nanosheets activate the toll-like receptor 
signaling cascades and trigger ensuing cytokine responses, which subsequently induce 
autophagy.411
The above reports indicate that nanoparticles may affect oxidative stress-dependent and -
independent pathways. BMP, growth factors and Mac-1 cascades are affected by direct 
interactions between signaling proteins and nanoparticles (BMPR-CNT, VEGF-GNP Mac-1 
receptor-GNP, respectively). These interactions do not necessarily induce oxidative stress 
and apoptosis but may affect proliferation or differentiation. Others signaling pathways such 
as MAPK, NF-κB and DNA damage are responsible for nanoparticle-induced oxidative 
stress. These events eventually cause cell death. All of these events are determined by both 
the nature of the nanoparticles and their surface chemistry. The control of nanoparticle-
induced signaling events and related cellular outcomes are crucial subjects for future 
investigations.
4.4.2. Global Biochemical Alterations by Nanoparticles—In contrast to small 
molecule drugs, for which the intracellular targets and mechanisms of action have been at 
least partially elucidated, knowledge of the molecular events involved in nanoparticle-
biological system interactions is limited. Nanoparticle-induced global biochemical 
alterations may provide useful insights into the molecular mechanisms and chemical basis of 
nanoparticle-biological systems interactions. The replication, transcription and translation of 
genes and synthesis of bioactive small molecules are biochemical processes that are 
controlled by tens of thousands of signals in response of intracellular demands or 
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extracellular stresses. Mapping these global profiles will facilitate the identification of 
nanoparticle-generated biological outcomes and the eventual regulation of these outcomes 
through modulation of the physicochemical properties of nanoparticles.
4.4.2.1. Genomic Transcriptional Profile: Unlike small molecules, which may 
significantly regulate > 5000 genes in living cells, most nanoparticles usually affect much 
fewer (< 500) genes, indicating that they may be less active and more selective toward 
cells.330,408,412-415 The biological activity of nanoparticles can be investigated via genomic 
transcriptional profiling. Carboxylated SWNTs inhibit Id genes in HEK293 cells in a whole 
genome background. BMP signaling, which targets Id genes, was identified through 
multiple assays.408 Pristine SWNTs or MWNTs affect a large number of genes related to the 
cell cycle, signaling transduction, apoptosis, oxidative stress, metabolism, transport and 
immune responses in human cells.398,414,416 By contrast, multi-walled carbon nano-onions 
affect genes that fall into the category of external stimuli other than the immune response.416 
PEG-modified SWNTs affect fewer genes, indicating a reduced biological activity.357 PEG-
modified, silica-coated QDs have been reported to affect 38 genes at low doses (8 nM) and 
12 genes at high doses (80 nM), with four shared genes. These genes are related to 
carbohydrate binding, intracellular vesicle localization and vesicular proteins involved in 
stress responses.412 Fe3O4 magnetic nanoparticles alter 711, 545 and 434 genes in mouse 
macrophage cells 4, 24 and 48 hours after treatment. MAPK, TLR and JAK-STAT signaling 
pathways are also affected by Fe3O4 nanoparticles. Bioinformatic analyses have revealed 
that these nanoparticles activate inflammatory and immune responses and inhibit 
biosynthesis and metabolism.415 In the absence of illumination, anatase TiO2 nanoparticles 
with diameters of 7, 20 and 200 nm upregulate the inflammatory response and cell adhesion 
genes but not oxidative stress genes in human keratinocytes.417 These effects indicate that 
TiO2 nanoparticles do not cause oxidative damage in the dark. Genomic expression profiles 
reveal that GNPs of smaller sizes (1.4 nm) upregulate heat shock and stress-related genes 
and lead to cell necrosis. However, larger GNPs (15 or 18 nm) affect fewer genes, indicating 
their superior biocompatibility.330,418 The toxicity of some metallic nanoparticles may be 
due to the release of the metal ions. Genomic transcriptional profiling reveals that silver 
nanoparticles affect 128 genes in human epithelial cells, similar to the response of cells 
exposed to silver ions.413 Treatment of epithelial cells with copper oxide nanoparticles 
upregulates genes in MAPK and downregulates cell cycle genes, also similar to cells treated 
with copper ions.419 These discoveries suggest that the release of metal ions from 
nanoparticles must be considered when evaluating the bioactivity of metallic nanoparticles.
4.4.2.2. Proteomic Expression: Protein synthesis is downstream of gene transcription and 
controlled by a number of regulatory factors. The evaluation of proteomic expression 
provides more relevant information than genomic transcriptome analyses. The global protein 
expression profile is generally examined using 2D gel electrophoresis combined with 
MS.420-422 Generally, total proteins extracted from cells are separated by 2D gel 
electrophoresis, and the protein spots on the gel are excised and digested, followed by MS 
analysis. The MS data are analyzed by searching databases to identify proteins. Another 
approach is the isobaric tags for relative and absolute quantitation (iTRAQ) technique.423 
iTRAQ uses liquid chromatography to separate isotopically labeled peptides and MS/MS 
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analysis to identify and quantitate peptides. Protein microarrays can be used for the high-
throughput evaluation of protein expression/phosphorylation.420 Antibodies against protein 
targets can be spotted on nitrocellulose membranes, enabling the detection of multiple 
proteins in a single experiment. Using the above technologies, proteomic expression/
phosphorylation profiles can be obtained. A total of 51 proteins in human hepatic carcinoma 
HepG2 cells are significantly affected by SWNTs, as detected by iTRAQ-coupled LC-
MS/MS analyses. These proteins are involved in metabolic pathways, redox regulation, 
signaling pathways, cytoskeleton formation and cell growth.423 Using 2D gel 
electrophoresis with MALDI-TOF MS, 45 altered proteins were identified in human 
monoblastic leukemia U937 cells in response to MWNTs. These proteins participate in 
metabolism, biosynthesis, stress response and differentiation processes.422 Additionally, 2D 
gel electrophoresis/MS analyses and protein phosphorylation antibody array analyses 
revealed that GNPs activate endoplasmic reticulum (ER) stress response in human chronic 
myelogenous leukemia K562 cells.420 A similar analysis indicated that TiO2 nanoparticles 
significantly alter 46 proteins in human bronchial epithelial BEAS-2B cells. These proteins 
are involved in the stress response, metabolism, adhesion, cytoskeletal dynamics, cell 
growth, cell death and signaling pathways. Nanoparticles perturb approximately 20 
proteomic pathways, consistent with pathways from genomic data analyses.421
4.4.2.3. Metabonomic Alterations: Nanoparticles cause physiological changes in living 
systems and generate altered metabolic profiles. Therefore, the investigation of global 
metabonomic profiles provides insight into the physiological processes that are perturbed by 
nanoparticles. Nanoparticle-induced metabonomic alterations are studied in live animals or 
in cells.424-427 Analytical methods that include 1H NMR, MS, HPLC-MS and gas 
chromatography-mass spectrometry (GC-MS) have been used in metabonomic analyses.424 
A global metabolism study in live cells using high-resolution MAS NMR spectroscopy 
demonstrated that silver nanoparticles decrease the levels of GSH, lactate, taurine and 
glycine and increase the levels of most amino acids, choline analogues and pyruvate. These 
results indicate that the depletion of GSH by nanoparticles may induce the conversion of 
lactate and taurine to pyruvate, providing a biochemical mechanism for oxidative stress.425 
HR-MAS 1H NMR was also used to study the metabonomic changes in RAW264.7 mouse 
macrophages following treatment with magnetic iron oxide nanoparticles. The nanoparticles 
caused a decrease in the levels of triglycerides, essential amino acids and choline 
metabolites while increasing glycerophospholipids, tyrosine, phenylalanine, lysine, glycine 
and glutamate. These changes reflect phagocytosis and cell membrane perturbation.427
In general, interactions between nanoparticles and biological systems include direct and 
indirect effects. Direct effects, such as the binding of nanoparticles to membrane 
phospholipids, receptors, cytosol proteins and DNA molecules, are modulated by the 
physicochemical properties of the biomacromolecules and nanoparticles and their 
microenvironment. Direct interactions are much more specific and material-dependent 
compared to indirect interactions and may have therapeutic potential. However, the 
investigation of direct interactions is challenging because of the complex cellular 
background. Indirect effects, such as signaling pathway activation by nanoparticle-induced 
ROS, cause cytotoxicity. Future investigations will enhance and regulate direct interactions 
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while minimizing indirect interactions. In this endeavor, chemical technology may be very 
powerful for modulating the biological activities of nanomaterials, as discussed below.
5. CHEMICAL APPROACHES TO REGULATE AND UNDERSTAND 
NANOPARTICLE-BIOLOGICAL SYSTEM INTERACTIONS
Interactions between nanoparticles and biological systems are complex. The biological 
activities of nanoparticles depend on their size, shape, structure and surface properties. As 
nanoparticle sizes fall into the nanometer range, the surface-exposed atoms increase 
exponentially. Therefore, changing the properties of the surface molecules may significantly 
alter the biological activities of nanoparticles. In this section, we explore various surface 
chemistry modification methods, the biological impacts of such modifications and 
computational models to predict the relationships between nanoparticle surface chemistries 
and their biological activities.
5.1. One-at-a-Time Nanoparticle Surface Chemistry Modification
5.1.1. Modulation of the Surface Chemistry of Nanoparticles—Various molecules 
have been used to modify nanomaterial surfaces via coating chemistry and consequently, 
their biological activity. Surface modification strategies include covalently or noncovalently 
linking small organic ligands or biomolecules to nanoparticles or encapsulating 
nanoparticles in surface coatings, such as polymers, micelles, liposomes,428 graphene 
oxide,141 and silica shells.412,429 The ligand exchange method is effective for transferring 
nanoparticles synthesized in organic solvents to aqueous media by displacing hydrophobic 
ligands on nanoparticles with water-soluble ligands. For example, dithiocarbamate moieties 
are designed to replace trioctylphosphine oxide capped on CdSe/ZnS QDs,430 while (3-
carboxypropyl)trimethylammonium chloride is used to replace lauric acid on Fe3O4 
nanocrystals.431 This ligand exchange step is essential to apply these nanoparticles in 
biological systems. The covalent linkage strategy requires the aid of coupling reagents, such 
as 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and N-hydroxysuccinimides, or Cu2+-
mediated click chemistry432 to react with functional groups on nanoparticles. Some 
nanoparticles with an aliphatic shell can be encapsulated in polymer coatings or micelles 
through an intercalating effect with amphiphilic polymers.433 In addition, the polymer 
coating can be achieved through a layer-by-layer technique by sequentially trapping 
nanoparticles in layers of polymers of alternating charge.434
5.1.2 Modulation of the Surface Charge of Nanoparticles—An acidic group is 
often used to generate nanoparticles with negative charges on their surfaces. Similarly, an 
amine group is used to generate nanoparticles with a positively charged surface. Surface-
charged nanoparticles differ greatly in their electrostatic and electrodynamic properties, 
which can be experimentally determined by ζ-potential measurements. Polystyrene 
nanoparticles with different surface functional groups, such as carboxylic acid, PEG, amine 
and amidine groups, have ζ-potential values ranging from −50 to 40 mV. The binding of 
serum proteins alters their ζ-potential values and narrows them to a range of −40 to −20 
mV.435 BSA, myoglobin and cytochrome C are adsorbed to mercaptoundecanoic acid-
protected GNPs, as shown by a quartz crystal microbalance study. All three proteins form 
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adsorption layers consisting of an irreversibly adsorbed layer and a reversibly adsorbed 
layer.109 These data suggest that the charged surface of a nanoparticle is quite complicated 
in solution. Multiple layers of molecules are adsorbed and dissociated constantly. The 
charged surface of nanoparticles also affects the conformation of the adsorbed proteins. 
Cytochrome C maintains its conformation when adsorbed to neutral GNPs, and it is 
denatured on the surface of charged GNPs.436 GNPs surface modified with charged and 
neutral amino acids affect the conformation and activity of α-chymotrypsin differently. 
Charged GNPs exhibit more effects than neutral particles.437 To understand the influence of 
surface charge density on protein binding, a series of polystyrene latex nanoparticles with 
the same size were prepared using different amounts of Na-styrenesulfonate comonomer. As 
the charge density increased, there was no change in the bound protein species, while the 
amount of adsorbed protein increased.438
The different electrostatic and electrodynamic properties of nanoparticles also modulate 
their interactions with cells. Such alterations include effects on cell internalization, cell 
function and cell death. A better understanding of these effects will not only help us design 
nanomaterials for biomedicinal applications, but will also elucidate mechanisms of 
nanotoxicity. Due to the presence of phosphate groups from lipids, cell membranes are 
negatively charged. Positively charged nanoparticles generally exhibit higher cell binding 
and cellular uptake than negatively charged nanoparticles. To understand the electrostatic 
and electrodynamic interactions between nanoparticles and cells with minimal secondary 
interactions, a nanoparticle library with a continuous change in the surface charge density 
was synthesized and investigated. The nanoparticle/cell interaction, however, did not exhibit 
a continuous change. Instead, a sharp increase in cell binding was observed as the positive 
surface charge density increased. The effective surface charge density on the outermost layer 
of the nanoparticle determined the electrostatic attraction between the nanoparticles and the 
cells.439 Nanoparticles with different charges induce different perturbations of the cell 
membrane potential. Positively charged nanoparticles depolarize the membrane, and 
negatively charged nanoparticles have a negligible effect. Membrane potential perturbations 
result in an increase in [Ca2+] influx, which in turn inhibits the proliferation of cells (Figure 
16).312 A method has been developed to differentiate GNPs bound to the cell surface from 
internalized GNPs. Neutral and negatively charged GNPs displayed lower cell membrane 
binding and cell internalization compared to positively charged nanoparticles.440
The surface charge effect seems applicable to a variety of nanomaterials. Positively charged 
GNPs, magnetic nanoparticles, silica nanoparticles and QDs all exhibit higher cellular 
uptake efficiency. (Figure 17).440 The internalization of negatively charged nanoparticles 
also occurs and is likely due to other interactions and subsequent endocytosis.441,442 QDs 
with a carboxylic acid surface coating are recognized by lipid rafts but not by clathrin or 
caveolae in human epidermal keratinocytes. QDs are internalized into early endosomes and 
then transferred to late endosomes or lysosomes. In addition, endocytic interfering agents 
have been used to investigate the mechanism by which QDs enter cells. The cellular uptake 
of QDs with negative surface charges is primarily regulated by pathways associated with G-
protein coupled receptors, low-density lipoprotein receptors and scavenger receptors.443
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In a kinetics study, positively charged nanoparticles displayed a higher rate of endocytosis 
than negative charged materials.444 Positively charged core-shell silica nanoparticles coated 
with polyethyleneimine have been shown to escape from endosomes and enter the 
cytoplasm and nucleus.445 Positively charged nanoparticles destabilize cell membranes and 
form holes or expand holes at pre-existing defects.446 The holes led to the internalization of 
nanoparticles into cells, as well as the diffusion of cytosolic proteins out of cells. Further 
studies have demonstrated that the formation of holes in lipid bilayers by positively charged 
nanoparticles is a common property regardless of the shape, size and chemical composition 
of the nanoparticles.447
5.1.3. Modulation of the Surface Hydrophobicity of Nanoparticles—The 
hydrophobicity of nanoparticles influences their ability to interact with biomolecules and 
cells. To investigate the correlation between plasma protein adsorption and the surface 
hydrophobicity of nanoparticles, latex nanoparticles with varied surface hydrophobicity 
were synthesized and examined. The number of bound proteins increased with increasing 
particle hydrophobicity, as determined by 2D polyacrylamide gel electrophoresis analyses 
and ITC. A clear difference in protein affinity for polymeric particles of different 
hydrophobicity has been observed.108,448
A set of polymethacrylate nanoparticles (140 nm) with fluorescence labels was investigated 
to reveal the relationship between particle hydrophobicity and cellular uptake. The monomer 
chain length controls the hydrophobicity of the modified nanoparticles, as evaluated by 
measuring the interfacial tensions between the monomers and water. The length of the 
monomer chains influences the cellular uptake of nanoparticles. Increasing the side chain 
length increases cellular uptake significantly. This phenomenon can be explained by the 
increased hydrophobicity and the softness of the particles.449
The surface hydrophobicity of nanoparticles is also modified by peptide–GNP hybrids. By 
altering the end amino acids of the peptide ligands, the uptake of GNPs can be dramatically 
increased or suppressed. Nanoparticles with tryptophan end groups enhance cellular uptake 
due to the membrane anchoring and permeation effects of the aromatic group.450
5.1.4. Changes in the Interactions of Nanoparticles with Biological Systems
5.1.4.1. Making Toxic Nanoparticles More Biocompatible: Nanoparticles may induce 
toxicity in biological systems because of their specific properties.451,452 One, the large 
surface area to volume ratio leads to very strong nonspecific interactions with biomolecules. 
These interactions will alter the conformation of proteins or DNA, resulting in their 
malfunction.453 Second, some nanoparticles are composed of heavy metals, such as CdTe 
and CdHgTe QDs. Under some conditions, the free metal ions may be released into 
biological systems and induce toxicity.454 Third, nanoparticles may induce ROS, such as 
free radicals (hydroxyl radical, ·OH; superoxide, ·O2−) and singlet oxygen (1O2) (e.g., 
QDs455 and Ag nanoparticles456). ROS are known to cause irreversible damage to nucleic 
acids, enzymes and cellular components that included the mitochondria, plasma and nuclear 
membrane. Fourth, some capping ligands derived from the nanoparticle synthesis system 
may induce cytotoxicity.457 Surface chemistry modifications may diminish the above side 
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effects and greatly improve the biocompatibility of potentially toxic nanoparticles. For 
example, the biocompatibility of QDs has been improved after surface modification with 
dendrimers,458,459 PEGylated dihydrolipoic acid,460,461 triblock copolymers,462 
cyclodextran463 and alkyl-modified poly(acrylic acid).464 The coating of SWNTs with 
polyvinylpyrrolidone polymers,465 phospholipid derivatives466 on silver nanoparticles or 
human serum protein467 also prevents their toxicity. Hexadecyltrimethylammonium bromide 
(CTAB) released from CTAB-coated Au NRs is highly cytotoxic at a nanoparticle 
concentration as low as 0.05 mM (20% cell viability). However, when toxic CTAB was 
replaced by PEG-SH, the cell viability when subjected to nanoparticles was 95%, even at a 
concentration of 0.5 mM.16 Similar effects have also been reported after the replacement or 
overcoating of CTAB with poly(sodium 4-styrenesulfonate),468 copolymer 
poly(diallyldimethylammonium chloride)/polystyrene sulfonic acid469 or polyallylamine 
hydrochloride.470
5.1.4.2. Regulating Interactions with Cells: The interaction of nanoparticles with cells is 
affected by the surrounding biomolecules in physiological media. When bare nanomaterials 
(particularly inorganic nanoparticles) encounter biological macromolecules, they may form 
a nanoparticle–macromolecule (mainly protein) corona hybrid nanostructure.453 Moreover, a 
secondary protein corona on the hybrid nanoparticles may be further formed via protein–
protein interactions. Some of these interactions do not occur in the native system in the 
absence of the nanoparticles, and an immunological response may be triggered. As a result, 
the nanohybrids are detected as foreign materials by the immune system. The nanohybrids 
are rapidly cleared from the blood stream and translocated to the liver and spleen,471 
potentially limiting the biological applications of nanoparticles. Fortunately, the fate of 
nanoparticles in biosystems can be regulated. Two main requirements, cell targeting and in 
vivo stealth properties, can be modulated by proper nanoparticle surface chemical 
modifications.
When a nanoparticle is presented to a cell, the cell first recognizes the coating molecules at 
the outermost layer of the nanoparticle. For targeting purposes, linking specific ligands to 
nanoparticles is necessary. Certain molecules, such as antibodies, aptamers or small-
molecule ligands, can bind to receptors overexpressed in tumor cells in a specific “lock-key” 
manner.428,472-475 After modification, nanohybrids are able to target specific cancer cells. 
This targeting strategy lays the foundation for designing nanomedicines for cancer diagnosis 
and therapy. The detection of circulating breast cancer cells in the blood was achieved by 
using a combination of an epithelial cell-specific, antibody-conjugated magnetic nanoprobes 
and anti-HER2 antibody-conjugated SERS tags.476 Because the HER2 receptors are highly 
expressed on the breast cancer cell membrane, the SERS tags recognized these tumor cells. 
Thus, the cancer cells were detected rapidly with good sensitivity. An anti-prostate antigen 
was conjugated to a multifunctional nanomedicine composed of loaded drugs, NIR QDs and 
a polystyrene matrix with internally embedded superparamagnetic Fe3O4 nanoparticles. 
Using this multifunctional nanoparticle, the specific detection of LNCaP prostate cancer 
cells was achieved.477
After being administered into the blood, most unmodified nanomaterials are taken up by the 
mononuclear phagocyte system within minutes or hours.478 Surface modification of 
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nanomaterials is generally regarded as a practical strategy to prevent protein adsorption and, 
consequently, avoid triggering immune responses.474 Various biocompatible polymer 
surface coatings, such as PEG,479 hyaluronic acid,480,481 cyclodextran482,483 and polymers 
based on phosphorylcholine484 provide effective barriers against protein bindings and 
therefore reduce both protein adsorption and cellular uptake. These modifications are widely 
used to impart stealth properties to nanoparticles in biomedical applications. These surface 
modifications also change the in vivo pharmacokinetics of nanoparticles.485 QDs modified 
with mPEG 5000 display a significantly prolonged in vivo circulation time in addition to 
reduced nonspecific accumulation in various organs.486 After surface PEGylation, the blood 
half-life of gold nanorods is increased to 24 h.457,487 PEG-terminated phospholipid was used 
to encapsulate QDs488 and iron oxide nanocrystals489 for a longer blood circulation time in 
vivo. A mPEG-alkyl-thiol polymer with an alkyl linker between the PEG and the thiol 
moiety yielded a much stronger Au nanoparticle surface protection compared to commonly 
used methoxy-PEG-thiol in the presence of cysteine and cystine molecules at the 
physiological concentrations.490 Surface coating of lipid molecules has also improved the 
pharmacokinetics of the silica nanoparticles.491
5.2. Combinatorial chemistry for Nanoparticle Modifications
The discovery and optimization of novel nanoparticles with unique properties by 
conventional methods has always been challenging and time consuming. High-throughput 
approaches, including parallel and combinatorial synthesis, are more efficient than 
conventional linear synthesis, and in recent years, these techniques have had an increasing 
impact in nanotechnology.
5.2.1 Parallel Chemistry for Nanoparticle Modifications—A parallel chemistry 
approach provides the opportunity to rapidly synthesize a large amount of nanoparticles with 
similar surface chemistries. However, this approach has limitations, mostly based on the 
lack of a general method to modify nanoparticles rapidly and the availability of small 
molecules that can be used.
5.2.1.1 Parallel Nanoparticle Libraries for Regulating Gene Delivery: Numerous 
biomaterials have been studied as potential nonviral gene delivery vectors to improve DNA 
stability and the efficiency of cellular uptake. The tested materials include inorganic 
surfactants, cationic lipids, polysaccharides, cationic polymers and dendrimers. These 
materials display small cargo capacity, inefficient uptake, poor biostability and low safety. 
Using high-throughput synthesis and screening techniques, libraries of poly-β-amino esters 
(PBAEs) of > 2000 members were synthesized to evaluate their gene delivery 
efficiency.492-494 A total of 46 PBAEs were superior to polyethylenimine. A second-
generation library of 486 polymers was synthesized to optimize the polymers and investigate 
their structure-function relationships.495 The best performing polymer nanoparticles were < 
150 nm and had positive surface charges. PBAEs have been used to deliver DNA to primary 
human endothelial cells.496 To investigate a larger PBAE chemical space, libraries of end-
modified PBAEs were also synthesized using various end-capping reagents.497,498 Two 
modified polymers with greatly improved transfection efficiency both in vitro and in vivo 
were discovered.
Mu et al. Page 35













5.2.1.2 Parallel Nanoparticle Libraries for Regulating Cell Targeting: Magnetic 
nanoparticles (MNPs) that target tissues of interest have been developed by conjugating 
antibodies, peptides499 or small molecules to the surface of MNPs.26,28 Small molecules 
with anhydride, amine, hydroxyl carboxyl, thiol and epoxy handles were coupled to the 
MNPs via different synthetic routes. The nanoparticles were printed on glass slides and 
showed different binding properties towards different targeting proteins using fluorescence 
detection. A collection of MNPs comprising 146 nanoparticles modified by different 
synthetic small molecules was synthesized and screened against different cell lines (Figure 
18). The In this screen, nanoparticles with high specificity for endothelial cells, pancreatic 
cancer cells or activated human macrophages were identified.28
5.2.1.3 Parallel Nanoparticle Libraries for Imaging: Weissleder et al. have developed 
fluorescent nanoparticles derivatized with small molecules using a parallel chemistry 
approach. Cellular uptake was rapidly profiled in vitro via binding of those nanoparticle 
imaging probes in primary cell isolates. This approach selects nanoparticles that display the 
desired targeting effects across all tested members of a class of cells and decreases the 
likelihood that an idiosyncratic cell line will unduly skew the screening results. The 
identified nanoparticle imaging probes were validated in vivo via intravital microscopy using 
pancreatic cancer mouse model.500 Although the molecular target of the probes remains to 
be discovered, the specific localization of these probes validates their respective use as in 
vivo neural tracers and cell discriminating agents.
5.2.1.4 Parallel Nanoparticle Libraries for Biosensors: Six functionalized poly(p-
phenyleneethynylene)s were used to construct a protein biosensor array containing six 
nanoprobes. These highly fluorescent polymer nanoparticles possessed various charge 
characteristics and molecular weights. In a proof-of-principle experiment, 17 protein 
analytes were successfully discriminated by their different fluorescence properties after 
nanoparticle binding. However, those probes were not tested in real samples, such as blood 
serum, containing complex mixtures of proteins with potentially interfering species.501 
Parallel modifications of magnetic nanoparticles aided in designing biomimetic nanoparticle 
biosensors with selectivity for specific cell types. The attachment of fluorescent molecules 
to magnetic nanoparticles permits the sorting or targeting of cells using both fluorescence-
based technologies and MR imaging.26,499 The conjugation of a lipoic acid-containing NIR 
active tricarbocyanine library to GNPs yielded probes with a strong SERS enhancement 
with 12-fold higher sensitivity than the current standard, 3,3'-diethylthiatricarbocyanine 
iodide. By further conjugating the probe to a scFv anti-HER2 antibody, this ultrasensitive 
SERS bioprobe was used for in vivo cancer imaging with the potential for use as a 
noninvasive diagnostic tool for HER-2-positive cancers.502
5.2.2 Nano-combinatorial Chemistry to Modify Nanoparticles—Compared with a 
parallel chemistry approach, combinatorial chemistry can provide a large number of 
different but structurally related molecules or materials. A series of nanoparticles with 
different surface coatings but the same core structure and different diversity points can be 
synthesized rapidly using nano-combinatorial chemistry. The number of compounds 
synthesized increases exponentially with the number of diversity points. Furthermore, 
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because the nanoparticles obtained by nano-combinatorial chemistry have surface coatings 
with similar structures, structure-activity relationships can be obtained, which is critical for 
computer-aided design for predicting nano-bio interactions.
5.2.2.1. Combinatorial Surface Modifications to Regulate Biocompatibility: Drug-
loaded nanoparticles with targeting ligands can grant them therapeutic, targeting or imaging 
functions. However, achieving a low blood clearance rate, low acute toxicity and a low 
immune response remains challenging. To discover biocompatible MWNTs without a priori 
knowledge of the related targets, our laboratory developed a computer-assisted, nano-
combinatorial synthetic library strategy. Combinatorial modifications of nanotube surfaces 
allowed us to map the unknown chemical space more effectively and rapidly. Computer-
aided design was used to select surface molecules to present the most diverse structural and 
physicochemical properties. As a result of multiple biological screenings, we identified 
nanomaterials with the most optimal biocompatibility and preliminary structure-activity 
relationship (Figure 19).27 Furthermore, to test the improved molecular recognition after 
surface modifications on MWNTs, the library was screened against α-chymotrypsin to 
compare the MWNT interactions with the enzyme catalytic site and other binding sites. Four 
of 80 MWNTs were found to significantly affect enzymatic catalysis with much less 
nonspecific bindings.503 The combinational chemistry modifications on MWNTs have also 
regulated immune perturbations in mice and in macrophages. In another example, a 
modified nanotube deterred the mannose surface receptor from binding to the scavenge 
receptor and reduced immunotoxicity.504
5.2.2.2. Combinatorial modifications to regulate cell targeting: Recently, we reported a 
dual-ligand gold nanoparticle library to discern the slight difference between cells that have 
different surface receptor profiles surrounding a common primary receptor.505 This library 
used folic acid as the primary targeting ligand. The secondary ligand was one of the ligands 
from a combinatorial library of 42 molecules. Cell recognition was investigated in four cell 
lines with various expressions of folate receptor (FR) and totally unknown secondary 
receptor profile. Cell binding and uptake in different cells were quite different, suggesting 
different receptor profiles surrounding the FRs. Furthermore, multivalent bindings of dual 
ligands can differentiate cells with high and low expression of FRs and enhance the contrast 
between these cells in radiation-induced cell death. This enhanced cell recognition and 
discrimination of cells with seemingly a common receptor provide an opportunity to treat 
patients at a personalized medicine level with a much better safety profile.505
5.2.2.3. Combinatorial Modifications to Regulate Cell Differentiation: Biomaterials can 
drive stem cells to an appropriate differentiation level and decrease the apoptosis of 
transplanted cells. We have observed that carboxylated MWNTs promote myogenic 
differentiation of mouse myoblast cells C2C12 and inhibit cell apoptosis under 
differentiation conditions.506 We explored the tuning of cell differentiation using 
combinatorial surface modifications on MWNTs. Different surface modifications conferred 
different modulations of binding to BMP receptor type II and caused different levels of 
suppression of the BMP signaling pathway. Modified MWNTs fine-tuned the downstream 
signaling through a series of bHLH proteins and myogenic differentiation. These results 
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demonstrated control of biological activities through surface-modified nanomaterials and 
opened an avenue for the potential application of nanomaterials in regenerative medicine.507
5.3. Computational Approaches to Elucidate Nano-Bio Interactions
The recent emergence and proliferation of experimental studies on the biological and 
toxicological activities of nanoparticles has created new challenges for computational 
scientists interested in rationalizing and exploiting these data by generating predictive 
models. Similar to data-rich areas of chemistry and biology, where the development of high-
throughput technologies and the accumulation of large amounts of data have spurred the 
establishment of cheminformatics and bioinformatics, we are beginning to witness the 
appearance of nanoinformatics, which naturally complements nanotechnology. For instance, 
a group of academic, governmental and industrial scientists interested in informatics 
opportunities in nanotechnology met at the first Nanoinformatics conference in 2010 (http://
nanotechinformatics.org/2010/overview). Presentations and idea exchanges at the 
conference led to the creation of the Nanoinformatics 2020 Roadmap (http://
eprints.internano.org/607/) as the “first broad-based community effort to articulate the 
comprehensive needs and goals in nanoinformatics”.
One of the most important components of nanoinformatics, which resonates with similar 
components of bio- and cheminformatics, concerns understanding the relationships between 
the structure and the physical and/or biological properties of nanoparticles. To this end, 
given that sufficient and organized data collections are available, well-established methods 
of quantitative structure activity relationship (QSAR) modeling, widely used in 
cheminformatics,508 could be expanded towards nanoparticles, as we have begun to 
advocate for recently.29,31 Herein, we provide a brief overview of the quantitative 
nanostructure-activity relationships (QNAR) modeling approach, which should help 
experimental scientists studying nanoparticle-biological systems interactions rationalize 
their data as well as employ QNAR models to enable the rational design of novel 
nanoparticles with the desired properties. We describe major principles and best practices in 
QSAR modeling, which serves as a basis for QNAR, and present a few recent examples of 
QNAR studies to illustrate the concept and its applicability to the computational modeling of 
nanoparticles.
5.3.1. Quantitative Structure-Activity Relationships (QSAR)—QSAR modeling has 
been a widely and successfully used approach in medicinal chemistry and drug discovery for 
nearly 50 years. The QSAR approach can be generally described as an application of data 
analysis methods and statistics to developing models for the accurate prediction of 
biological activities or properties of compounds based on their structures. Any QSAR 
method can be generally defined as an application of mathematical and statistical methods to 
the problem of finding empirical relationships (QSAR models) of the form 
, where Pi are the biological activities (or other properties of interest) 
of the molecules, D1, D2,…,Dn are calculated (occasionally experimentally measured) 
structural properties (molecular descriptors) of the compounds, and  is some empirically 
established mathematical transformation that should be applied to descriptors to calculate 
the property values for all molecules. The goal of QSAR modeling is to develop a 
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computational means of predicting compound target properties (e.g., specific bioactivities or 
toxicities) from their chemical structure, as characterized with computed chemical 
descriptors or, in some cases, by experimental physical chemical characteristics. All QSAR 
approaches directly or indirectly imply simple similarity principles, which for some time 
have provided a foundation for experimental medicinal chemistry: compounds with similar 
structures are expected to have similar biological activities. The detailed description of 
major tenets of QSAR modeling is beyond the scope of this paper; the overview of many 
popular QSAR modeling techniques, including statistical and data mining techniques and 
descriptor calculation approaches, can be found in many reviews and monographs).509,510
For brevity, we shall comment on the most critical general aspects of model development 
and, most importantly, validation, which are especially significant in the context of using 
QSAR models for identifying novel hit compounds by virtual screening. Additional essential 
information concerning both common errors and established practices in the QSAR 
modeling field can be found in other critical essays on the subject.511,512 We emphasize 
such aspects because they are generic for any QSAR-based approach application (i.e., 
QNAR) to enable rigorous model development.
The strategy for developing extensively validated and externally predictive QSAR models is 
summarized in Figure 20 (described in more detail elsewhere513). We begin by carefully 
curating chemical structures and, if possible, associated biological activities to prepare the 
dataset for subsequent calculations. Then, a fraction of compounds (generally, 10-20%) is 
selected randomly as an external evaluation set. A more rigorous n-fold external validation 
protocol can be employed when the dataset is randomly divided into n nearly equal parts. 
The n-1 parts are then systematically used for model development, and the remaining 
fraction of compounds is used for model evaluation. The remaining subset of compounds 
(the modeling set) is divided into multiple training and test sets. The training sets are used to 
establish correlations between values of chemical descriptors and those of biological 
activities or other target properties; the models are validated internally for their ability to 
accurately predict the target properties of compounds in the test sets. All of the models that 
display high prediction accuracy for both the training and the test set form an ensemble that 
is applied to predict target properties for compounds in the external evaluation set. The 
critical step of the external validation is the use of the applicability domains,514 which is 
defined uniquely for each model used in the consensus (ensemble) prediction of the external 
set. If external validation demonstrates the significant predictive power of the models, we 
employ the models for virtual screening of available chemical databases (e.g., ZINC515) to 
identify putative active compounds and work with collaborators who could experimentally 
validate such hits.
We shall emphasize two of the most important aspects of the QSAR modeling workflow that 
directly pertain to QNAR modeling. First, the most critical difference between any chemical 
datasets that the QSAR modeling strategy is applied to is the type of descriptors used to 
characterize the compounds. Thus, the selection of the most appropriate descriptors of 
nanoparticles is the main challenge for developing QNAR strategies. Second, models 
resulting from the predictive QSAR modeling workflow (Fig. 1) can be used in virtual 
screening to prioritize the selection of chemicals for the experimental validation. In fact, it is 
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increasingly critical to include experimental validation as the ultimate assertion of the 
model-based prediction. This paradigm fully applies to the use of QNAR modeling in 
nanotechnology as described in the next section.
5.3.2. QNAR modeling: Applications to the Rational Design of Nanoparticles 
with Desired Bioactivity Profiles—The evaluation of both the desired and undesired 
biological effects of nanoparticles is of critical importance for the future of nanotechnology. 
Predictive QNAR modeling can be used, by analogy with QSAR, to establish statistically 
significant relationships between the measured biological effects of nanoparticles and their 
physical, chemical and geometrical properties. As follows from the previous section, 
modeling of the biological effects of nanoparticles is possible if they can be characterized by 
descriptors. Figure 21 illustrates two different categories of nanoparticle datasets: those 
comprising nanoparticles with diverse metal cores and organic decorations, for which only 
experimentally measured properties (i.e., size, shape, zeta potential, morphology, surface 
area, chemical reactivity, chemical composition and aspect ratio) can be used as descriptors 
and those involving nanoparticles possessing the same core (e.g., CNTs) but different 
surface-modifying organic molecules, for which descriptors can be calculated for a single 
representative of the surface-modifying molecule. Several commercially available software 
packages, such as Dragon,516 MOE517 and ISIDA,518 could compute hundreds to thousands 
of theoretical descriptors for any single compound directly from its molecular structure. To 
illustrate the possible applications of the QNAR method, we describe several case studies 
for which we constructed and validated models (Figure 22).
5.3.2.1. Modeling of Cellular Effects Induced by Diverse Nanoparticles using 
Experimentally Measured Properties as Descriptors: In a study, 51 diverse nanoparticles 
were tested in various cell-based assays.30 All nanoparticles were tested in vitro against four 
cell lines in four different assays at four different concentrations, resulting in a 51 × 64 
biological data matrix of experimental results. Each cell of this matrix reported the 
biological activity profile induced by a given nanoparticle at a certain concentration in a 
particular assay for a given cell line. Assay response values were expressed in units of 
standard deviations of the distribution obtained when control cells were treated with 
phosphate buffered saline (PBS) alone: ZNP = (μNP - μPBS) / σPBS, where μPBS is the mean 
of the control tests with PBS, and σPBS is its standard deviation. The authors also reported 
four experimentally measured descriptors for 44 of 51 tested nanoparticles: size, two types 
of relaxivities and zeta potential.
We have demonstrated the feasibility of deriving robust QNAR models using the following 
four experimental descriptors: size, two types of relaxivities and zeta potential. Four such 
structural descriptors were available for 44 of the 51 nanoparticles. To capture 
nanoparticles’ activity across a broader swath of biology, the Shaw group measured the 
effects of nanoparticles in four diverse cell line, at four doses and using four assays that 
interrogate different aspects of cellular physiology. Thus, the biological effects of each 
nanomaterial can be described as a 64-feature vector (4 cell lines × 4 assays × 4 doses).
In theory, 64 independent QNAR models could be developed, with each model attempting to 
reproduce the biological response induced by 44 nanoparticles for a given assay in a 
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particular cell line at a given dose; however, we were unable to develop statistically 
significant models. Therefore, we combined the entire 64-dimensional vector for each 
nanoparticle into a single averaged response. We then defined two binary classes using an 
arbitrary threshold at Zmean = −0.40 to enable a binary classification of nanoparticles. Two 
groups, each containing the same number of nanoparticles, were thus defined: 22 
nanoparticles belonged to class 1 (Zmean ≥ −0.40), and the remaining 22 were placed in class 
0 (Zmean < −0.40).31
The WinSVM program (a Windows implementation of a support vector machine) developed 
in-house was used to derive QNAR classification models. A rigorous 5-fold external cross-
validation was followed to validate the models; under this procedure, the program splits the 
entire dataset five times into a modeling set including 80% of nanoparticles and the external 
validation set, comprising the remaining 20% of nanoparticles. Only the modeling set 
(which is divided additionally into multiple training and test sets) was used to build and 
validate models, and models with reasonable training and test set prediction power were 
selected for predicting the class membership of the external set. Importantly, each 
nanoparticles was included in a validation set only once, allowing us to calculate the overall 
external prediction accuracy for the whole set.
The results demonstrated that the SVM models yielded an external prediction as high as 
73% for the entire set of 44 nanoparticles. Within five independent external folds, prediction 
performances led from 56 to 88% accuracy. Apparently, the combination of biological 
profiles into one single binary classification scheme allowed us to detect the overall 
biological signal from noise and thus obtain QNAR models with both good internal fitness 
and external predictive power.
5.3.2.2. Modeling of Nanoparticle Uptake in PaCa2 Cancer Cells using Computational 
Descriptors: Whether the multivalent attachment of small organic molecules to the same 
nanoparticles can increase their specific binding affinity to certain cells without a priori 
knowledge of the cell target was investigated.519 A combinatorial library of 109 
nanoparticles was synthesized in which a superparamagnetic nanoparticle (cross-linked iron 
oxide with amine groups, CLIO-NH2) was decorated with different synthetic small 
molecules. Nanoparticles were screened against different cell lines, including PaCa2 human 
pancreatic cancer cells, U937 macrophage cell lines, resting and activated primary human 
macrophages and human umbilical vein endothelial cells (HUVECs). In contrast to the other 
cell lines, the uptake of the nanoparticles in PaCa2 pancreatic cancer cells were diverse and 
highly dependent on surface modification, enabling the application of the QSAR modeling 
approach to these data. We represented each individual nanoparticle by the structure of a 
single, organic molecule decorating its surface. Thus, each nanoparticle was represented by 
a unique set of descriptor values determined for the conjugated small molecule.
Using this representation, we have developed statistically significant models by relying on 
chemical descriptors and nanoparticle cellular uptake. The models' external prediction power 
was shown to be as high as R2 = 0.72 and a mean absolute error of 0.18 under a 5-fold 
external validation procedure.31 This study suggests that the cellular behavior of a series of 
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nanoparticles sharing a common core can be reasonably well predicted using QNAR models 
built with the descriptors of surface modifying ligands only.
5.3.2.3. QNAR Models as Tools for Designing CNTs with Desired Biological Properties: 
CNTs are among the most well-known nanoparticles, particularly in the area of drug 
delivery.520-523 We utilized a combinatorial synthesis technique to decorate the CNTs’ large 
surface area with a series of congeneric organic molecules and investigated the overall 
toxicity of this series of nanoparticles.ENREF 522 A total of 84 CNTs were tested in several 
in vitro toxicological assays, including protein binding assays (BSA, carbonic anhydrase, 
chymotrypsin and hemoglobin), acute toxicity assays (survival percentage) and immune 
toxicity assays (secretion of nitric oxide), all at two different doses (7.5 and 15 μg/mL). All 
of the CNTs shared the same core structure, and thus the variability of their biological/
toxicological behavior could be interpreted only based on the surface modifications.27
Each CNT was represented with a unique organic molecule from its coating surface, similar 
to the study described above, and chemical descriptors were calculated for each molecule. 
We assigned a binary toxicity class (1 as toxic and 0 as non-toxic) to each CNT based on the 
acute toxicity assay and the toxicity measured for pristine CNTs (CNTs with no surface 
modifiers). Only strong and weak CNT toxicants were considered for the modeling: 38 
strong toxicants (class 1) vs. 35 weak toxicants (class 0) were subjected to QNAR modeling 
using the Random Forest approach. Similarly to other case studies, we realized a 5-fold 
external cross-validation. The results were surprisingly good with an overall external 
prediction accuracy as high as 74% (n = 73, sensitivity = 79%, specificity = 69%). We also 
developed QNAR models using protein-binding profiles that yielded 77% external 
prediction accuracy for classifying strong vs. weak CNT protein binders.
These models have been employed for the virtual screening of a large library of 240,000 
potential CNT surface modifiers in order to identify those with desired properties (low 
toxicity, low binding affinity for carbonic anhydrase). Ten compounds that were predicted to 
be toxic and ten compounds that were predicted to be non-toxic were selected for the 
experimental validation. The preliminary results suggest that all predictions for non-toxic 
compounds were accurate, and for six out ten compounds predicted to be toxic, the 
experimental results were in agreement with the computational annotation.
We conclude that analogous to conventional applications of QSAR modeling for the 
analysis of bioactive organic molecules, QNAR models can be useful for predicting activity 
profiles of novel nanoparticles, either from their experimental or computationally derived 
descriptors and for designing and manufacturing safer nanoparticles with desired properties. 
However, a shortage of systematic experimental data that characterize the constitutional, 
physical and chemical properties of nanoparticles remains. In addition, no standard set of 
biological assays has been clearly defined to objectively and relevantly evaluate the in vitro 
(and in vivo) effects of tested CNTs. The development of systematized data repositories 
through collective efforts of experimental and computational scientists will enable the 
development of new and highly valuable QNAR models capable of rationally guiding 
further experimental studies toward safer and more effective nanoparticles.
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A double-edged sword, nanotechnology provides us with enormous opportunities while 
posing a potential threat to human health. Therefore, understanding how engineered 
nanoparticles interact with biological systems is urgent and critical. Nanoparticles are 
known to cause organ damage in experimental animals and even in human. Such damages 
are the direct or indirect results of perturbations of cells and biological molecules such as 
proteins, lipids, DNA and small molecules by nanoparticles. The nature and magnitude of 
nanoparticle interactions with biological molecules are determined by both the biological 
molecules and engineered nanoparticles themselves.
The fundamental physicochemical properties of nanoparticles, such as their surface charge, 
hydrophobicity and chemical bonding interactions, play significant roles in nano-bio 
interactions. Nanoparticles with different physicochemical properties exhibit different 
interactions with biological systems. For example, they may be surrounded by protein 
coronas of different nature, bind to different cell membrane proteins, enter or perturb cells 
differently or exhibit diverse compatibility with physiological systems. A systematic 
understanding of such chemical interactions will help elucidate the QNAR of nano-bio 
interactions. Such an understanding also facilitates the generation of nanomaterials through 
safe-by-design processes.
Based on these considerations, the intentional surface modification of nanomaterials by one-
at-a-time, parallel or combinatorial synthesis has been shown to alter nano-bio interactions. 
Such effects have encouraged the development of biocompatible or bio-targeting 
nanoparticles. Another significant development is that nano-bio interactions can now be 
predicted by computational chemistry. These experimental and theoretical approaches have 
strengthened our understanding of the chemical basis of nano-bio interactions and provide 
unprecedented methodologies to proactively design and manufacture safe nanomaterials for 
a sustainable nanotechnology era.
However, the investigation of nano-bio interactions is by no means complete. Many 
challenges remain. First, we must understand the mechanisms of nano-bio interactions with 
greater clarity via a better characterization of experimental systems, such as nanoparticles. 
Due to their chemical nature and their interactions with microenvironmental molecules, the 
chemical identity, biological identity or cellular identity of nanoparticles may differ. 
Comprehensive characterization will improve our understanding of such interaction 
mechanisms, and QNAR studies can be conducted with better accuracy. Moreover, diverse 
findings from different laboratories can be compared to form a systematic knowledge base. 
Second, at the cellular level, an interaction with a receptor protein leads to a network of 
cellular signaling and the release of numerous molecules for signal propagation, feedback 
and adaptation. Therefore, an in-depth understanding of nano-bio interactions at the cellular 
level relies on the future development of systems biology and related knowledge bases. 
Third and most significant, at the physiological level, the impact of nanoparticles on human 
health is an end result of complicated interplays of complex interactions. For example, 
nanoparticles always adsorb environmental pollutants and perturb cellular nutrient 
molecules and redox balance, yielding multipronged effects. Furthermore, such toxicant 
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exposures are due to various sources and last a lifetime, beginning with a fertilized egg. 
Therefore, research aimed at understanding nano-bio interactions is an integral part of 
exploration in chemical biology and toxicology, having unique features. Therefore, it relies 
on the future progress of the chemical and biological sciences.
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LIST OF ABBREVIATIONS
AFM atomic force microscopy
ATP adenosine-5'-triphosphate
BMP bone morphogenetic protein
BMPR2 bone morphogenetic protein receptor type II
BSA bovine serum albumin
CB carbon black
CD circular dichroism
CLSM confocal laser scanning microscopy
CNTs carbon nanotubes
CTAB hexadecyltrimethylammonium bromide
DLS dynamic light scattering
DNA deoxyribonucleic acid
DPPC dipalmitoyl phosphatidylcholine




FCS fluorescence correlation spectroscopy
FTIR Fourier-transform infrared spectroscopy
GC-MS gas chromatography-mass spectrometry
GNPs gold nanoparticles
GO graphene oxide
GPCRs G protein coupled receptors
GSH glutathione
Hb hemoglobin
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HSA human serum albumin
HSQC NMR heteronuclear single quantum coherence nuclear magnetic resonance
HUVECs human umbilical vein endothelial cells
ITC isothermal titration calorimetry
iTRAQ isobaric tags for relative and absolute quantitation
LB Langmuir-Blodgett
LC-MS liquid chromatography mass spectroscopy
MALDI TOF-MS matrix-assisted laser desorption-ionization time-of-flight mass 
spectrometry
MAPK mitogen-activated protein kinase
MAS NMR magic angle spinning nuclear magnetic resonance
MNPs magnetic nanoparticles
MS mass spectrometry
MWNTs multi-walled carbon nanotubes
NF-κB nuclear factor kappa B
NIR near infrared
NMR nuclear magnetic resonance
PBAEs poly-β-amino esters
PBS phosphate buffered saline
PEG polyethylene glycol
PRINT particle replication in non-wetting template
QCM quartz crystal microbalance
QDs quantum dots
QNAR quantitative nanostructure activity relationships
QSAR quantitative structure-activity relationships
RNA ribonucleic acid
RNS reactive nitrogen species
ROS reactive oxygen species
RT-PCR reverse transcription polymerase chain reaction
SEM scanning electron microscopy
SERS surface-enhanced Raman spectroscopy
SPR surface plasma resonance
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SVM support vector machine
SWNTs single-walled carbon nanotubes
TEM transmission electron microscopy
TGF-β transforming growth factor beta
TLR Toll-like receptor
TOF MS time-of-flight mass spectrometry
UV-Vis ultraviolet-visible
VEGF vascular endothelial growth factor
XPS X-ray photoelectron spectroscopy
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Interactions of nanoparticles with biological systems at different levels. Nanoparticles enter 
the human body through various pathways, reaching different organs and contacting tissues 
and cells. All of these interactions are based on nanoparticle-biomacromolecule associations.
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An analysis of literature statistics indicates growing concern for the topics that are the focus 
of this review. The number of publications and citations were obtained using the keywords 
“nanoparticles” and “biological systems” in the subject area of “Chemistry” when searching 
the Thomson Reuters (ISI) Web of Knowledge for the period 1994-2012.
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A nanoparticle-induced surface reconstruction of phospholipid membranes. A phospholipid 
bilayer vesicle with bound nanoparticles is shown. Binding of anionic nanoparticles to the 
lipid bilayer in the fluid phase causes a transition to gel phase at the site at which the 
nanoparticle binds. Binding-induced reorientation of the phosphocholine (PC) head group 
causes lipids in the fluid phase to exhibit a lower density (A) than in the gel phase (B). In the 
PC head group, P− and N+ are denoted by blue and red, respectively. Reprinted with 
permission from ref 73. Copyright 2011 National Academy of Sciences, USA.
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The potential inhibitory effects of GNPs on pulmonary surfactants in the alveolar space. (a) 
A continuous surfactant film (monolayer and underlying multilayer) forms after the rupture 
of pulmonary surfactant vesicles at the air-liquid interface as the hypothetical rate-limiting 
intermediate structure between bilayer vesicles and the interfacial monolayer. (b) The 
disrupted interfacial surfactant film due to the entrapment of GNPs (from the air phase as 
pollutants) by pulmonary surfactant is depicted. (c) The self-aggregation of lipid-capped 
GNPs in the presence of surfactant protein B is shown in red. Reprinted with permission 
from ref 57. Copyright 2008 Cell Press.
Mu et al. Page 66














Two-dimensional (2D) [15N-1H]-HSQC NMR spectra of free human ubiquitin (red) and 
human ubiquitin plus GNPs (yellow) at pH 7.7, showing chemical shift perturbation for 
some NH groups upon interaction with GNPs. The black arrows indicate the NH backbone 
groups with the largest chemical shift perturbations (Q2, L15, and E18) in this spectral 
window. Reprinted with permission from ref 104. Copyright 2010 American Chemical 
Society.
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Identification of peptides associated with nanoparticle-protein interactions by cross-linking 
and MS. (A) A schematic illustration of the detection principle. (B) MALDI-MS spectra of 
released peptides when human serum albumin was (a) cross-linked and (b) adsorbed to the 
polyacrylic acid-Fe3O4 nanoparticles. The analysis of the supernatant from the cross-linked 
and noncross-linked samples is shown in (c) and (d), respectively. A peak of m/z 1640 in Ba 
indicates a peptide cross-linked onto the nanoparticle surface; in the supernatant, the peak 
intensity is significantly reduced (Bc). The arrows in Bc indicate three of thirteen identified 
peptides with consistently reduced peak intensity in supernatant samples. Reprinted with 
permission from ref 105. Copyright 2011 American Chemical Society.
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Interactions between bovine fibrinogen, immunoglobulin, transferrin, bovine serum albumin 
and SWNTs. Molecular modeling illustrations of proteins (in bead representation) binding to 
SWNTs after incubation for 10 min (A) and 5 h (B). (C) The locations of the most preferred 
binding sites on proteins for SWNTs. The residues highlighted in the van der Waals 
representation correspond to tyrosine (red) and phenylalanine (green). The other regions of 
the protein are presented in pink. (D) The detailed orientations of the aromatic rings of the 
tyrosine and phenylalanine residues interacting with the six-membered rings of SWNTs are 
represented in silver. The tyrosine residues are rendered as licorice representations (red), 
while the phenylalanine residues are shown in green. Adapted from ref 52 with permission. 
Copyright 2011 National Academy of Sciences, USA.
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PEG density-based determination of the composition of the adsorbed serum protein corona 
on the surface of GNPs. Adsorbed serum proteins were isolated from 15-nm GNPs grafted 
with PEG at varying densities, purified, digested with trypsin and characterized by LC-
MS/MS. Proteins were clustered into one of four groups: A, B, C or D (represented by the 
colored bars), based on the correlation of their relative abundance across PEG densities. 
PEG/nm2: number of PEG molecules per square nanometer. Reprinted from ref 181 with 
permission. Copyright 2012 American Chemical Society.
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Orientation of the bound DNA bases relative to the SWNT axis. The green arrows and 
wavelengths indicate the directions and wavelengths of optical dipole transitions, 
respectively. Reprinted with permission from ref 194. Copyright 2007 American Chemical 
Society.
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Illustration of DNA undergoing a conformational transition from B form (top) to Z form 
(bottom) on a carbon nanotube. Reprinted with permission from ref 211. Copyright 2006 
American Association for the Advancement of Science.
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TEM of T4 DNA complexes with L (large, 40 nm), M (medium, 15 nm) and S (small, 10 
nm) nanoparticles and schematic representations of the complexes. Reprinted with 
permission from ref 240. Copyright 2007 Cell Press.
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Receptor-mediated cellular uptake and translocation of nanoparticles.
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(A) A schematic illustration of the effect of GNP surface charge on their cellular uptake by a 
typical mammalian cell. (B) The electrostatic attraction between nanoparticles and cells. (a) 
The surface charge density of a GNP library. (b) Cellular uptake of these GNPs in HeLa 
cells, as determined by ICP-MS. Reprinted with permission from ref 301 and 302. Copyright 
2010 & 2012 American Chemical Society.
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Changing polystyrene nanoparticles from a three-dimensional (3D) spherical shape to a 2D 
disk shape promotes their cell surface binding, with significant reduction of cell uptake. (A) 
Experimental evidence of a nanodisk reducing cellular uptake. (B) The model for reduced 
cellular uptake but enhanced cell surface binding by nanodisks. Reprinted from ref 25 with 
permission. Copyright 2012 American Chemical Society.
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A schematic diagram showing the molecular interactions involved in MWNT 1-enhanced 
cell differentiation and apoptosis inhibition. Reprinted with permission from ref 405. 
Copyright 2012 Nature Publishing Group.
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Schematic depicting the surface charge effects of GNPs on cellular function. Reprinted from 
ref 311 with permission. Copyright 2010 American Chemical Society.
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Schematics illustrating the interactions between cells and nanoparticles with different types 
of surface charges: (A) negatively and neutrally charged nanoparticles. (B) Positively 
charged nanoparticles. Reprinted from ref 439 with permission. Copyright 2009 American 
Chemical Society.
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(A) Model of the cross-linked dextran coating modified with small molecules. Different 
classes of small molecules with amino, sulfhydryl, carboxyl or anhydride functionalities 
were anchored onto nanoparticles and stored in multi-well plates for testing. (B) Part of a 
heat map representing the cellular uptake of different nanoparticle preparations. Columns 
from right to left: 1, pancreatic cancer cells (PaCa-2); 2, macrophage cell line (U937); 3, 
resting primary human macrophages; 4, activated primary human macrophages; 5, human 
umbilical vein endothelial cells (HUVEC). Each column represents mean values from six 
different experiments. Red indicates the lowest accumulation, and green indicates the 
highest accumulation. Reprinted with permission from ref 28. Copyright 2005 Nature 
Publishing Group.
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(A) Surface molecular compositions of combinatorial MWNT library members. (B) The 
multi-assay score of the f-MWNT library from four protein binding assays, cytotoxicity and 
immune response assays (at 50 μg/mL) were ranked for all library members. The sum of 
their ranks was designated the multi-assay score and is shown as vertical bars in the graph. 
The structures of the optimal hits are shown. Reprinted from ref 27 with permission. 
Copyright 2008 American Chemical Society.
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General workflow for the development of validated and externally predictive QSAR models.
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The applications of QNAR methods to nanomaterials with either diverse cores 
(characterized by experimental properties) or similar cores but diverse surface modifiers 
(characterized by computed chemical descriptors of modifying organic molecules). Adapted 
from ref 31 with permission. Copyright 2010 American Chemical Society.
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Unsupervised hierarchical clustering of CNTs uncovered common subgroups for both 
protein binders (red) and non-binders (blue). (A) The heat map represents the protein 
binding activities of the CNTs, which are sorted according to the dendrogram. The red color 
indicates high activity, while the blue represents low activity. (B) The red cluster represents 
four compounds consisting of a common substituent (ethyl benzoate, highlighted in the red 
square) causing similar (high) protein binding responses as measured in four different 
assays. (C) The blue cluster represents five compounds consisting of a common substructure 
(benzene chloride) highlighted in the blue square. These compounds behave similarly (low) 
activity in four protein binding assays. BSA, bovine serum albumin; CA, carbonic 
anhydrase; CT, α-chymotrypsin; HB, hemoglobin.
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Factors influencing nanoparticle-biomolecule interactions.
Mu et al. Page 85
Chem Rev. Author manuscript; available in PMC 2015 September 22.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
